# Altria Group, Inc.: Form 10-Q for the period ended Jun 30, 2014

- Company: [Altria Group, Inc.](/companies/mo.md) (CIK 764180)
- Form: 10-Q
- Filed: 2014-07-22
- Accepted by EDGAR: Jul 22, 2014, 10:49 ET
- Period: 2014-06-30
- Accession: 0000764180-14-000059
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/764180/000076418014000059/a2014form10-qq22014.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/764180/000076418014000059/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2014-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2014-04-01 to 2014-06-30 | $6.26bn | us-gaap:SalesRevenueNet |
| Revenue | 6 months, 2014-01-01 to 2014-06-30 | $11.77bn | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2014-04-01 to 2014-06-30 | $1.97bn | us-gaap:CostOfGoodsSold |
| Cost of revenue | 6 months, 2014-01-01 to 2014-06-30 | $3.72bn | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months, 2014-04-01 to 2014-06-30 | $2.60bn | us-gaap:GrossProfit |
| Gross profit | 6 months, 2014-01-01 to 2014-06-30 | $4.86bn | us-gaap:GrossProfit |
| Operating income | 3 months, 2014-04-01 to 2014-06-30 | $1.98bn | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2014-01-01 to 2014-06-30 | $3.71bn | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2014-04-01 to 2014-06-30 | $683.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2014-01-01 to 2014-06-30 | $1.31bn | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2014-04-01 to 2014-06-30 | $1.26bn | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2014-01-01 to 2014-06-30 | $2.44bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2014-04-01 to 2014-06-30 | $0.64 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months, 2014-01-01 to 2014-06-30 | $1.23 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months, 2014-01-01 to 2014-06-30 | $759.0m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 6 months, 2014-01-01 to 2014-06-30 | $60.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months, 2014-01-01 to 2014-06-30 | $1.91bn | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 6 months, 2014-01-01 to 2014-06-30 | $404.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2014-06-30 | $1.19bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2014-06-30 | $4.47bn | us-gaap:AssetsCurrent |
| Total assets | at 2014-06-30 | $33.28bn | us-gaap:Assets |
| Current liabilities | at 2014-06-30 | $5.05bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2014-06-30 | $28.86bn | us-gaap:Liabilities |
| Long-term debt | at 2014-06-30 | $13.99bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2014-06-30 | $0 | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | at 2014-06-30 | $0 | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2014-06-30 | $4.39bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 131,833 characters.

### Description of the Company

At June 30, 2014, Altria Group, Inc.’s wholly-owned subsidiaries included Philip Morris USA Inc. (“PM USA”), which is engaged in the manufacture and sale of cigarettes and certain smokeless tobacco products in the United States; John Middleton Co. (“Middleton”), which is engaged in the manufacture and sale of machine-made large cigars and pipe tobacco, and is a wholly-owned subsidiary of PM USA; and UST LLC (“UST”), which through its wholly-owned subsidiaries, including U.S. Smokeless Tobacco Company LLC (“USSTC”) and Ste. Michelle Wine Estates Ltd. (“Ste. Michelle”), is engaged in the manufacture and sale of smokeless tobacco products and wine. Altria Group, Inc.’s other operating companies included Nu Mark LLC (“Nu Mark”), a wholly-owned subsidiary, which is engaged in the manufacture and sale of innovative tobacco products, and Philip Morris Capital Corporation (“PMCC”), a wholly-owned subsidiary, which maintains a portfolio of leveraged and direct finance leases. Other Altria Group, Inc. wholly-owned subsidiaries included Altria Group Distribution Company, which provides sales, distribution and consumer engagement services to Altria Group, Inc.’s operating subsidiaries, and Altria Client Services Inc., which provides various support services, such as legal, regulatory, finance, human resources and external affairs, to Altria Group, Inc.’s operating subsidiaries. In addition, Nu Mark and its subsidiaries, and Middleton use third-party contract manufacturing arrangements in the manufacture of their products. Altria Group, Inc.’s access to the operating cash flows of its wholly-owned subsidiaries consists of cash received from the payment of dividends and distributions, and the payment of interest on intercompany loans by its subsidiaries. At June 30, 2014, Altria Group, Inc.’s principal wholly-owned subsidiaries were not limited by long-term debt or other agreements in their ability to pay cash dividends or make other distributions with respect to their common stock.

At June 30, 2014, Altria Group, Inc. also held approximately 27% of the economic and voting interest of SABMiller plc (“SABMiller”), which Altria Group, Inc. accounts for under the equity method of accounting. Altria Group, Inc. receives cash dividends on its interest in SABMiller if and when SABMiller pays such dividends.

Altria Group, Inc.’s reportable segments are smokeable products, smokeless products and wine. The financial services and the alternative products businesses are included in an all other category.

Certain prior-period amounts have been reclassified to conform with the current-period presentation, due primarily to the reclassification of changes in book overdrafts on Altria Group, Inc.’s condensed consolidated statements of cash flows to operating activities. These amounts were previously classified as financing activities.

### Executive Summary

The following executive summary is intended to provide significant highlights of the *Discussion and Analysis* that follows.

*Consolidated Results of Operations for the Six Months Ended June 30, 2014*: The changes in Altria Group, Inc.’s net earnings and diluted earnings per share (“EPS”) attributable to Altria Group, Inc. for the six months ended June 30, 2014, from the six months ended June 30, 2013, were due primarily to the following:

*(in millions, except per share data)*

|  | Net Earnings | Diluted EPS |
| --- | ---: | ---: |
| For the six months ended June 30, 2013 | $2,651 | $1.32 |
| 2013 NPM Adjustment Items | (334) | (0.16) |
| 2013 Asset impairment and exit costs | 1 | — |
| 2013 Tobacco and health litigation items | 4 | — |
| 2013 SABMiller special items | 7 | — |
| Subtotal 2013 special items | (322) | (0.16) |
| 2014 NPM Adjustment Items | 56 | 0.03 |
| 2014 Asset impairment, exit, integration and acquisition-related costs | (1) | — |
| 2014 Tobacco and health litigation items | (23) | (0.01) |
| 2014 SABMiller special items | (21) | (0.01) |
| Subtotal 2014 special items | 11 | 0.01 |
| Fewer shares outstanding | — | 0.01 |
| Change in tax rate | 21 | 0.01 |
| Operations | 76 | 0.04 |
| For the six months ended June 30, 2014 | $2,437 | $1.23 |

*See the discussion of events affecting the comparability of statement of earnings amounts in the Consolidated Operating Results section of the following Discussion and Analysis.*

*Fewer Shares Outstanding:* Fewer shares outstanding during the six months ended June 30, 2014 compared with the prior-year period were due primarily to shares repurchased by Altria Group, Inc. under its share repurchase programs.

*Operations*: The increase of $76 million in operations shown in the table above was due primarily to the following:

- higher income from the smokeable products and smokeless products segments; and
- lower interest and other debt expense, net;

partially offset by:

- lower income from the financial services business;
- higher investment spending in the alternative products businesses; and
- lower earnings from Altria Group, Inc.’s equity investment in SABMiller.

*For further details, see the Consolidated Operating Results and Operating Results by Business Segment sections of the following Discussion and Analysis.*

*Consolidated Results of Operations for the Three Months Ended June 30, 2014*: The changes in Altria Group, Inc.’s net earnings and diluted EPS attributable to Altria Group, Inc. for the three months ended June 30, 2014, from the three months ended June 30, 2013, were due primarily to the following:

*(in millions, except per share data)*

|  | Net Earnings | Diluted EPS |
| --- | ---: | ---: |
| For the three months ended June 30, 2013 | $1,266 | $0.63 |
| 2013 NPM Adjustment Items | (23) | (0.01) |
| 2013 SABMiller special items | (2) | — |
| Subtotal 2013 special items | (25) | (0.01) |
| 2014 NPM Adjustment Items | 15 | 0.01 |
| 2014 Tobacco and health litigation items | (20) | (0.01) |
| 2014 SABMiller special items | (15) | (0.01) |
| Subtotal 2014 special items | (20) | (0.01) |
| Fewer shares outstanding | — | 0.01 |
| Change in tax rate | 11 | — |
| Operations | 30 | 0.02 |
| For the three months ended June 30, 2014 | $1,262 | $0.64 |

*See the discussion of events affecting the comparability of statement of earnings amounts in the Consolidated Operating Results section of the following Discussion and Analysis.*

*Fewer Shares Outstanding:* Fewer shares outstanding during the three months ended June 30, 2014 compared with the prior-year period were due primarily to shares repurchased by Altria Group, Inc. under its April 2013 share repurchase program.

*Operations*: The increase of $30 million in operations shown in the table above was due primarily to the following:

- higher income from the smokeable products and smokeless products segments; and
- lower interest and other debt expense, net;

partially offset by:

- higher investment spending in the alternative products businesses; and
- lower income from the financial services business.

*For further details, see the Consolidated Operating Results and Operating Results by Business Segment sections of the following Discussion and Analysis.*

*2014 Forecasted Results*: In July 2014, Altria Group, Inc. revised its 2014 full-year forecast for reported diluted EPS to a range of $2.54 to $2.59 from a range of $2.53 to $2.60. The 2014 full-year reported diluted EPS forecast reflects the impact of the items detailed in the table below, as compared with 2013 full-year reported diluted EPS of $2.26, which included $0.12 per share of net expenses, as detailed in the table below. In addition, in July 2014, Altria Group, Inc. revised its 2014 full-year forecast for adjusted diluted EPS, which excludes the impact of the items detailed in the table below, representing a growth rate of 7% to 9% over 2013 full-year adjusted diluted EPS. Altria Group, Inc. expects higher adjusted diluted EPS growth in the second half of 2014, particularly in the fourth quarter, driven by various factors. These include lower fourth-quarter costs in the smokeable products segment due to the end of the federal tobacco quota buy-out payments and a lower fourth-quarter of 2014 effective tax rate on operations compared to the fourth quarter of 2013 resulting from Altria Group, Inc’s 2013 debt tender offer.

The factors described in the *Cautionary Factors That May Affect Future Results* section of the following *Discussion and Analysis* represent continuing risks to this forecast and to the other forward-looking statements made in this Quarterly Report on Form 10-Q (“Form 10-Q”).

*(Income) Expense, Net Included in Reported Diluted EPS*

|  | 2014 | 2013 |
| --- | ---: | ---: |
| NPM Adjustment Items | $(0.03) | $(0.21) |
| Asset impairment, exit, integration and acquisition-related costs | 0.01 | — |
| Tobacco and health litigation items | 0.01 | 0.01 |
| SABMiller special items | 0.01 | 0.01 |
| Loss on early extinguishment of debt | — | 0.34 |
| Tax items | — | (0.03) |
|  | $— | $0.12 |

Adjusted diluted EPS is a financial measure that is not consistent with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Altria Group, Inc.’s management reviews diluted EPS on an adjusted basis, which excludes certain income and expense items that management believes are not part of underlying operations. These items may include, for example: loss on early extinguishment of debt; restructuring charges; SABMiller special items; certain tax items; tobacco and health litigation items; and settlements of, and determinations made in connection with, disputes with certain states and territories related to the non-participating manufacturer (“NPM”) adjustment provision under the 1998 Master Settlement Agreement (the “MSA”) for the years 2003 - 2012 (such settlements and determinations are referred to collectively as “NPM Adjustment Items” and are more fully described in *Health Care Cost Recovery Litigation - Possible Adjustments in MSA Payments for 2003 - 2013* in Note 9. *Contingencies* to the condensed consolidated financial statements in Item 1. Financial Statements in this Form 10-Q (“Item 1”). Altria Group, Inc.’s management does not view any of these special items to be part of its sustainable results as they may be highly variable and difficult to predict and can distort underlying business trends and results. Altria Group, Inc.’s management believes it is appropriate to disclose this non-GAAP financial measure to provide useful insight into underlying business trends and results, and to provide a more meaningful comparison of year-over-year results. Adjusted measures are used by management and regularly provided to Altria Group, Inc.’s chief operating decision maker for planning, forecasting and evaluating business and financial performance, including allocating resources and evaluating results relative to employee compensation targets. This information should be considered as supplemental in nature and not considered in isolation or as a substitute for the related financial information prepared in accordance with U.S. GAAP.

### Discussion and Analysis

### Consolidated Operating Results

*(in millions)*

| Net revenues: | For the Six Months Ended June 30, 2014 | 2013 | For the Three Months Ended June 30, 2014 | 2013 |
| --- | ---: | ---: | ---: | ---: |
| Smokeable products | $10,569 | $10,646 | $5,611 | $5,678 |
| Smokeless products | 879 | 848 | 464 | 458 |
| Wine | 275 | 263 | 146 | 137 |
| All other | 50 | 76 | 35 | 32 |
| Net revenues | $11,773 | $11,833 | $6,256 | $6,305 |
| Excise taxes on products: |  |  |  |  |
| Smokeable products | $3,118 | $3,265 | $1,644 | $1,741 |
| Smokeless products | 66 | 59 | 36 | 33 |
| Wine | 10 | 10 | 5 | 5 |
| Excise taxes on products | $3,194 | $3,334 | $1,685 | $1,779 |
| Operating income: |  |  |  |  |
| Operating companies income: |  |  |  |  |
| Smokeable products | $3,320 | $3,646 | $1,789 | $1,726 |
| Smokeless products | 524 | 492 | 285 | 270 |
| Wine | 50 | 45 | 28 | 25 |
| All other | (54) | 93 | (53) | 43 |
| Amortization of intangibles | (10) | (10) | (5) | (5) |
| General corporate expenses | (121) | (113) | (69) | (58) |
| Operating income | $3,709 | $4,153 | $1,975 | $2,001 |

As discussed further in Note 6. *Segment Reporting* to the condensed consolidated financial statements in Item 1, Altria Group, Inc.’s chief operating decision maker reviews operating companies income to evaluate the performance of and allocate resources to the segments. Operating companies income for the segments excludes general corporate expenses and amortization of intangibles. Management believes it is appropriate to disclose this measure to help investors analyze the business performance and trends of the various business segments.

The following events that occurred during the six and three months ended June 30, 2014 and 2013 affected the comparability of statement of earnings amounts:

- **NPM Adjustment Items:** For the six and three months ended June 30, 2014 and 2013, pre-tax income for NPM Adjustment Items was recorded in Altria Group, Inc.’s condensed consolidated statements of earnings as follows:

*(in millions)*

|  | For the Six Months Ended June 30, 2014 | 2013 | For the Three Months Ended June 30, 2014 | 2013 |
| --- | ---: | ---: | ---: | ---: |
| Smokeable products segment | $43 | $519 | $43 | $36 |
| Interest and other debt expense, net | 47 | — | (17) | — |
| Total | $90 | $519 | $26 | $36 |

- 69-

The amounts shown in the table above for the smokeable products segment were recorded by PM USA as reductions to cost of sales, which increased operating companies income in the smokeable products segment. For further discussion, see *Health Care Cost Recovery Litigation - Possible Adjustments in MSA Payments for 2003 - 2013* in Note 9. *Contingencies* to the condensed consolidated financial statements in Item 1 (“Note 9”).

- **Tobacco and Health Litigation Items:** For the six and three months ended June 30, 2014 and 2013, pre-tax charges related to certain tobacco and health litigation items were recorded in Altria Group, Inc.’s condensed consolidated statements of earnings as follows:

*(in millions)*

|  | For the Six Months Ended June 30, 2014 | 2013 | For the Three Months Ended June 30, 2014 | 2013 |
| --- | ---: | ---: | ---: | ---: |
| Smokeable products segment | $19 | $5 | $16 | $— |
| General corporate expenses | 15 | — | 15 | — |
| Interest and other debt expense, net | 1 | 1 | — | — |
| Total | $35 | $6 | $31 | $— |

During the second quarter of 2014, Altria Group, Inc. and PM USA recorded an aggregate pre-tax charge of $31 million in marketing, administration and research costs for the estimated costs of implementing the corrective communications remedy in connection with the federal government’s lawsuit against Altria Group, Inc. and PM USA. For further discussion, see *Health Care Cost Recovery Litigation - Federal Government’s Lawsuit* in Note 9.

#### Consolidated Results of Operations for the Six Months Ended June 30, 2014

The following discussion compares consolidated operating results for the six months ended June 30, 2014 with the six months ended June 30, 2013.

Net revenues, which include excise taxes billed to customers, decreased $60 million (0.5%), due primarily to lower net revenues in the smokeable products segment.

Excise taxes on products decreased $140 million (4.2%), due primarily to lower smokeable products shipment volume.

Cost of sales increased $449 million (13.7%), due primarily to the higher NPM Adjustment Items in 2013.

Marketing, administration and research costs increased $84 million (7.8%), due primarily to higher investment spending in the alternative products businesses and lower reductions to the allowance for losses in the financial services business.

Operating income decreased $444 million (10.7%), due primarily to lower operating results from the smokeable products segment (which includes higher NPM Adjustment Items in 2013), lower income from the financial services business, and higher investment spending in the alternative products businesses, partially offset by higher operating results from the smokeless products segment.

Interest and other debt expense, net, decreased $142 million (27.0%), due primarily to lower interest costs on debt as a result of debt maturities in 2013 and 2014, and debt refinancing activities during 2013, as well as interest income recorded during the first half of 2014 as a result of the NPM Adjustment Items.

Altria Group, Inc.’s income tax rate decreased 0.5 percentage points to 35.0% due primarily to an increased recognition of foreign tax credits in 2014, primarily associated with SABMiller dividends.

Net earnings attributable to Altria Group, Inc. of $2,437 million decreased $214 million (8.1%), due primarily to lower operating income and lower earnings from Altria Group, Inc.’s equity investment in SABMiller, partially offset by lower interest and other debt expense, net, and a lower income tax rate. Diluted and basic EPS attributable to Altria Group, Inc. of $1.23, each decreased by 6.8% due to lower net earnings attributable to Altria Group, Inc., partially offset by fewer shares outstanding.

#### Consolidated Results of Operations for the Three Months Ended June 30, 2014

The following discussion compares consolidated operating results for the three months ended June 30, 2014 with the three months ended June 30, 2013.

Net revenues, which include excise taxes billed to customers, decreased $49 million (0.8%), due primarily to lower net revenues in the smokeable products segment.

Excise taxes on products decreased $94 million (5.3%), due primarily to lower smokeable products shipment volume.

Marketing, administration and research costs increased $86 million (15.6%), due primarily to higher investment spending in the alternative products businesses, charges in connection with the federal government’s lawsuit against Altria Group, Inc. and PM USA, and a reduction to the allowance for losses during 2013 in the financial services business.

Operating income decreased $26 million (1.3%), due primarily to higher investment spending in the alternative products businesses and lower income from the financial services business, partially offset by higher operating results from the smokeable products and smokeless products segments.

Interest and other debt expense, net, decreased $34 million (12.9%), due primarily to lower interest costs on debt as a result of debt maturities in 2013 and 2014, and debt refinancing activities during 2013, partially offset by a reduction of previously recorded interest income related to the NPM Adjustment Items.

Net earnings attributable to Altria Group, Inc. of $1,262 million was essentially unchanged as lower operating income and lower earnings from Altria Group, Inc.’s equity investment in SABMiller were mostly offset by lower interest and other debt expense, net. Diluted and basic EPS attributable to Altria Group, Inc. of $0.64, each increased by 1.6% due to fewer shares outstanding.

### Operating Results by Business Segment

### Tobacco Space

### Business Environment

### Summary

The United States tobacco industry faces a number of business and legal challenges that have adversely affected and may adversely affect the business and sales volume of our tobacco subsidiaries and our consolidated results of operations, cash flows or financial position. These challenges, some of which are discussed in more detail below, in Note 9 and in *Cautionary Factors That May Affect Future Results*, include:

- pending and threatened litigation and bonding requirements;
- the requirement to issue “corrective statements” in various media in connection with the federal government’s lawsuit;
- restrictions and requirements imposed by the Family Smoking Prevention and Tobacco Control Act (“FSPTCA”) enacted in June 2009, and restrictions and requirements that have been, and in the future will be, imposed by the U.S. Food and Drug Administration (“FDA”) under this statute;
- actual and proposed excise tax increases, as well as changes in tax structures and tax stamping requirements;
- bans and restrictions on tobacco use imposed by governmental entities and private establishments and employers;
- other federal, state and local government actions, including:
- increases in the minimum age to purchase tobacco products above the current federal minimum age of 18;
- restrictions on the sale of tobacco products by certain retail establishments, the sale of certain tobacco products with certain characterizing flavors and the sale of tobacco products in certain package sizes;
- additional restrictions on the advertising and promotion of tobacco products;
- other actual and proposed tobacco product legislation and regulation; and
- governmental investigations;
- the diminishing prevalence of cigarette smoking and increased efforts by tobacco control advocates and others (including employers and retail establishments) to further restrict tobacco use;
- price gaps and changes in price gaps between premium and lowest price brands;
- competitive disadvantages related to cigarette price increases attributable to the settlement of certain litigation;
- illicit trade in tobacco products; and
- potential adverse changes in tobacco leaf price, availability and quality.

In addition to and in connection with the foregoing, evolving adult tobacco consumer preferences pose challenges for Altria Group, Inc.’s tobacco subsidiaries. Our tobacco subsidiaries believe that a significant number of adult tobacco consumers switch between tobacco categories or use multiple forms of tobacco products and that approximately 50% of adult smokers say they are interested in trying innovative tobacco products. Altria Group, Inc.’s tobacco subsidiaries further believe that adult tobacco consumer awareness of electronic cigarettes is high and growing. Nu Mark estimates that total consumer expenditures for e-vapor products were approximately $1 billion in the United States in 2013 and believes that expenditures on these products continue to grow in 2014.

Altria Group, Inc. and its tobacco subsidiaries work to meet these evolving adult tobacco consumer preferences over time by developing, manufacturing, marketing and distributing products both within and outside the United States through innovation and adjacency growth strategies (including, where appropriate, arrangements with, or investments in, third parties). For example, Nu Mark entered the e-vapor category in 2013 with the introduction of *MarkTen* e-vapor products into two lead markets. Nu Mark began the national expansion of *MarkTen* products on June 2, 2014. In addition, as further discussed in Note 2. *Acquisition of Green Smoke*, on April 1, 2014, Nu Mark completed the acquisition of the e-vapor business of Green Smoke, Inc. and its affiliates (“Green Smoke”). See the discussions regarding new product technologies, adjacency growth strategy and evolving consumer preferences in *Cautionary Factors That May Affect Future Results* below for certain risks associated with the foregoing discussion.

We have provided additional detail on the following topics below:

- FSPTCA and FDA Regulation;
- Excise Taxes;
- International Treaty on Tobacco Control;
- State Settlement Agreements;
- Other Federal, State and Local Regulation and Activity;
- Illicit Trade in Tobacco Products;
- Tobacco Price, Availability and Quality; and
- Timing of Sales.

### FSPTCA and FDA Regulation

### The Regulatory Framework

The FSPTCA expressly establishes certain restrictions and prohibitions on our cigarette and smokeless tobacco businesses and authorizes or requires further FDA action. Under the FSPTCA, the FDA has broad authority to (1) regulate the design, manufacture, packaging, advertising, promotion, sale and distribution of cigarettes, cigarette tobacco and smokeless tobacco products; (2) require disclosures of related information; and (3) enforce the FSPTCA and related regulations. The law also grants the FDA authority to extend the FSPTCA’s application, by regulation, to all other tobacco products, including cigars, pipe tobacco and electronic cigarettes.

Among other measures, the FSPTCA:

- imposes restrictions on the advertising, promotion, sale and distribution of tobacco products, including at retail;
- bans descriptors such as “light,” “mild” or “low” or similar descriptors unless expressly authorized by the FDA;
- requires extensive ingredient disclosure to the FDA and may require more limited public ingredient disclosure;
- prohibits any express or implied claims that a tobacco product is or may be less harmful than other tobacco products without FDA authorization;
- imposes reporting obligations relating to contraband activity and grants the FDA authority to impose recordkeeping and other obligations to address illicit trade in tobacco products;
- changes the language of the cigarette and smokeless tobacco product health warnings, enlarges their size and requires the development by the FDA of graphic warnings for cigarettes, and gives the FDA the authority to require new warnings;
- authorizes the FDA to adopt product regulations and related actions, including:
- to impose tobacco product standards that are appropriate for the protection of the public health through a regulatory process, including, among other possibilities, restrictions on ingredients, constituents or other properties, performance or design criteria, as well as to impose testing, measurement, reporting and disclosure requirements;
- to subject tobacco products that are modified or first introduced into the market after March 22, 2011 to application and pre-market review and authorization requirements (the “New Product Application Process”) if the FDA does not find them to be “substantially equivalent” to products commercially marketed as of February 15, 2007, and to deny any such new product application, thus preventing the distribution and sale of any product affected by such denial;
- to determine that certain existing tobacco products modified or introduced into the market for the first time between February 15, 2007 and March 22, 2011 are not “substantially equivalent” to products commercially marketed as of February 15, 2007, in which case the FDA could require the removal of such products or subject them to the New Product Application Process and, if any such applications are denied, prevent the continued distribution and sale of such products (see *FDA Regulatory Actions* below);
- to restrict or otherwise regulate menthol cigarettes, as well as other tobacco products with characterizing flavors (see *TPSAC* below);
- to regulate nicotine yields and to reduce or eliminate harmful constituents or harmful ingredients or other components of tobacco products; and
- to impose manufacturing standards for tobacco products; and
- equips the FDA with a variety of investigatory and enforcement tools, including the authority to inspect tobacco product manufacturing and other facilities.

In April 2014, the FDA issued proposed regulations for other tobacco products, which as proposed would include machine-made large cigars, e-vapor products such as electronic cigarettes, pipe tobacco and chewable tobacco-derived nicotine products marketed and sold by some of our tobacco subsidiaries. The proposed regulations would impose the FSPTCA regulatory framework, including the foregoing measures, on products manufactured, marketed and sold by Nu Mark and Middleton with potentially wide-ranging impact. Nu Mark and Middleton intend to submit comments on the proposed regulations by the August 8, 2014 comment period deadline.

### Implementation Timing, Rulemaking and Guidance

The implementation of the FSPTCA began in 2009 and will continue over time. Some provisions took effect immediately, some provisions have taken effect since the enactment of the FSPTCA and other provisions will not take effect for some time. Those provisions that require the FDA to take action through rulemaking generally involve consideration of public comment and, for some issues, scientific review. Altria Group, Inc.’s tobacco subsidiaries participate actively in processes established by the FDA to develop and implement the FSPTCA’s regulatory framework, including submission of comments to various FDA proposals and participation in public hearings and engagement sessions.

From time to time, the FDA also issues guidance for public comment, which may be issued in draft or final form. Such guidance, when finalized, is intended to represent the FDA’s current thinking on a particular topic and may be predictive of the FDA’s enforcement stance on that topic. Such guidance, even when finalized, is not intended to bind the FDA or the public or establish legally enforceable responsibilities. For example, the FDA has issued draft guidance on topics such as modified risk tobacco product applications, applications for pre-market review of new tobacco products and demonstrating substantial equivalence of a new tobacco product.

A complete set of guidance documents issued by the FDA can be found on the FDA’s website at www.fda.gov/TobaccoProductsGuidanceComplianceRegulatoryInformation/default.htm. The information on this website is not, and shall not be deemed to be, part of this report or incorporated into any other filings Altria Group, Inc. makes with the Securities and Exchange Commission (“SEC”).

Altria Group, Inc.’s tobacco subsidiaries submit comments to the FDA on draft or final guidance when appropriate. In some cases, our tobacco subsidiaries may disagree with a particular interpretation by the FDA as expressed in draft or final guidance and may communicate their position in writing to the FDA. For example, PM USA and USSTC communicated disagreement with FDA interpretations of the statute set forth in the “Draft Guidance for Industry and FDA Staff: Demonstrating the Substantial Equivalence of a New Tobacco Product: Responses to Frequently Asked Questions” regarding when a manufacturer must submit substantial equivalence reports. While PM USA and USSTC believe that all of their current products meet the statutory requirements of the FSPTCA, they cannot currently predict whether, when or how the FDA ultimately will apply its guidance or seek to enforce the law and regulations consistent with its guidance. As discussed below in *Investigations and Enforcement*, FDA enforcement actions could have a material adverse effect on the business, consolidated results of operations, cash flows or financial position of Altria Group, Inc. and its tobacco subsidiaries.

The implementation of the FSPTCA and related regulations and guidance also may have an impact on enforcement efforts by states, territories and localities of the United States of their laws and regulations as well as of the State Settlement Agreements discussed below (see *State Settlement Agreements* below). Such enforcement efforts may adversely affect our tobacco subsidiaries’ ability to market and sell regulated tobacco products in those states, territories and localities.

### Impact on Our Business; Compliance Costs

Regulations imposed and other regulatory actions taken by the FDA under the FSPTCA could have a material adverse effect on the business, consolidated results of operations, cash flows or financial position of Altria Group, Inc. and its tobacco subsidiaries in a number of different ways. For example, actions by the FDA could:

- impact the consumer acceptability of tobacco products;
- delay, discontinue or prevent the sale or distribution of existing, new or modified tobacco products;
- limit adult consumer choices;
- restrict communications to adult consumers;
- create a competitive advantage or disadvantage for certain tobacco companies;
- impose additional manufacturing, labeling or packaging requirements;
- impose additional restrictions at retail;
- result in increased illicit trade in tobacco products; or
- otherwise significantly increase the cost of doing business.

The failure to comply with FDA regulatory requirements, even inadvertently, and FDA enforcement actions could also have a material adverse effect on the business, consolidated results of operations, cash flows or financial position of Altria Group, Inc. and its tobacco subsidiaries.

The FSPTCA imposes fees on tobacco product manufacturers and importers to pay for the cost of regulation and other matters. The cost of the FDA user fee is allocated first among tobacco product categories subject to FDA regulation according to a process set out in the statute, which relies, in part, on the allocation methodology set forth in the Fair and Equitable Tobacco Reform Act of 2004 (“FETRA”), and then among manufacturers and importers within each respective category based on their relative market shares. In May 2013, the FDA issued proposed regulations to govern the allocation of the FDA user fee when the FETRA program concludes after the third quarter of 2014. An Altria Group, Inc. subsidiary filed comments on behalf of PM USA and USSTC objecting to certain aspects of the proposed regulations. On July 10, 2014, the FDA issued final regulations adopting the FETRA methodology for allocating the FDA user fee among tobacco product categories. For a discussion of the impact of the State Settlement Agreements, the FETRA and FDA user fee payments on Altria Group, Inc., see *Financial Review - Debt and Liquidity - Payments Under State Settlement and Other Tobacco Agreements, and FDA Regulation* below. In addition, compliance with the FSPTCA’s regulatory requirements has resulted and will continue to result in additional costs for our tobacco businesses. The amount of additional compliance and related costs has not been material in any given quarter to date but could become material, either individually or in the aggregate, and will depend on the nature of the requirements imposed by the FDA.

### Investigation and Enforcement

The FDA has a number of investigatory and enforcement tools available to it, including document requests and other required information submissions, facility inspections, examinations and investigations, injunction proceedings, money penalties, product withdrawals and recalls, and product seizures. The use of any of these investigatory or enforcement tools by the FDA could result in significant costs to the tobacco businesses of Altria Group, Inc. or otherwise have a material adverse effect on the business, consolidated results of operations, cash flows or financial position of Altria Group, Inc. and its tobacco subsidiaries.

For example, in June 2010, the FDA issued a document request regarding changes to *Marlboro* Gold Pack cigarette packaging in connection with the FSPTCA’s ban of certain descriptors. PM USA submitted documents in response to the FDA’s request.

### TPSAC

#### The Role of the TPSAC

As required by the FSPTCA, the FDA has established a tobacco product scientific advisory committee (the “TPSAC”), which consists of voting and non-voting members, to provide advice, reports, information and recommendations to the FDA on scientific and health issues relating to tobacco products. For example, the TPSAC advises the FDA about modified risk products (products marketed with reduced risk claims), good manufacturing practices, the effects of the alteration of nicotine yields from tobacco products and nicotine dependence thresholds. The TPSAC previously made reports and recommendations to the FDA on menthol cigarettes, including the impact of the use of menthol in cigarettes on the public health, and the nature and impact of dissolvable tobacco products on the public health. The FDA may seek advice from the TPSAC about other safety, dependence or health issues relating to tobacco products, including tobacco product standards and applications to market new tobacco products.

#### TPSAC Membership

Beginning in March 2010, PM USA and USSTC raised with the FDA their concerns that four of the voting members of the TPSAC have financial and other conflicts (including services as paid experts for plaintiffs in tobacco litigation) that could hamper the full and fair consideration of issues by the TPSAC and requested that their appointments be withdrawn. PM USA and USSTC raised similar concerns related to the engagement of two TPSAC subcommittee consultants. The FDA declined PM USA’s and USSTC’s requests, stating that the FDA had satisfied itself, after inquiry, that the individuals in question did not have disqualifying conflicts of interest. In February 2011, Lorillard Tobacco Company (“Lorillard”) and R.J. Reynolds Tobacco Company (“R.J. Reynolds”) filed suit in the U.S. District Court for the District of Columbia against the United States Department of Health and Human Services and individual defendants (sued in their official capacities) asserting that the composition of the TPSAC and the composition of the Constituents Subcommittee of the TPSAC violates several federal laws, including the Federal Advisory Committee Act. The government defendants filed their motion for summary judgment as to all claims in June 2013. Lorillard and R.J. Reynolds filed a cross-motion for summary judgment in July 2013. On July 21, 2014, the district court granted plaintiffs’ summary judgment motion, in part, and denied defendants’ summary judgment motion. The court ordered the FDA to reconstitute the TPSAC and barred defendants from relying on the TPSAC report on menthol, discussed below.

#### TPSAC Action on Menthol

As mandated by the FSPTCA, in March 2011, the TPSAC submitted to the FDA a report on the impact of the use of menthol in cigarettes on the public health and related recommendations. The TPSAC report stated that “\[m\]enthol cigarettes have an adverse impact on public health in the United States.” The TPSAC report recommended that the “\[r\]emoval of menthol cigarettes from the marketplace would benefit public health in the United States.” The TPSAC report noted the potential that any ban on menthol cigarettes could lead to an increase in contraband cigarettes and other potential unintended consequences and suggested that the FDA consult with appropriate experts on this matter. The TPSAC report also recommended that additional research could address gaps in understanding menthol cigarettes.

In March 2011, PM USA submitted a report to the FDA outlining its position that neither science nor other evidence demonstrates that regulatory actions or restrictions related to the use of menthol cigarettes are warranted. The report noted PM USA’s belief that significant restrictions on the use of menthol cigarettes would have unintended consequences detrimental to public health and society. In July 2011, the TPSAC revised and approved its March 2011 report. The revisions were editorial in nature and did not change the substantive conclusions and recommendations of the TPSAC.

The FSPTCA does not set a deadline or required timeline for the FDA to act on the TPSAC report. The FDA has stated that the TPSAC report is only a recommendation and that the FDA’s receipt of the TPSAC report will not have an immediate effect on the availability of menthol cigarettes. Moreover, as noted above, the FDA is subject to a July 21, 2014 court order that bars it from relying on the TPSAC report.

In January 2012, the FDA announced that it had evaluated scientific information on menthol and had drafted a report related to the impact of menthol in cigarettes on public health. The FDA indicated that it had sent its report to external scientists for peer review. In July 2013, the FDA released its preliminary scientific evaluation, which states “that menthol cigarettes pose a public health risk above that seen with non-menthol cigarettes.” At the same time, the FDA also issued an advance notice of proposed rulemaking requesting comments on the FDA’s preliminary scientific evaluation and information that may inform potential regulatory actions regarding menthol in cigarettes or other tobacco products. In November 2013, PM USA submitted comments to the FDA raising a number of concerns with the preliminary scientific evidence, including comments demonstrating that menthol cigarettes do not affect population harm differently than non-menthol cigarettes. PM USA also reiterated that significant restrictions on the use of menthol in cigarettes would have unintended consequences detrimental to public health and society. No future action can be taken by the FDA to regulate the manufacture, marketing or sale of menthol cigarettes (including a possible ban) until the completion of the rulemaking process.

### Final Tobacco Marketing Rule

As required by the FSPTCA, the FDA re-promulgated in March 2010 certain advertising and promotion restrictions in substantially the same form as regulations that were previously adopted in 1996 (but never imposed on tobacco manufacturers due to a United States Supreme Court ruling) (the “Final Tobacco Marketing Rule”). The Final Tobacco Marketing Rule:

- bans the use of color and graphics in tobacco product labeling and advertising;
- prohibits the sale of cigarettes and smokeless tobacco to underage persons;
- restricts the use of non-tobacco trade and brand names on cigarettes and smokeless tobacco products;
- requires the sale of cigarettes and smokeless tobacco in direct, face-to-face transactions;
- prohibits sampling of cigarettes and prohibits sampling of smokeless tobacco products except in qualified adult-only facilities;
- prohibits gifts or other items in exchange for buying cigarettes or smokeless tobacco products;
- prohibits the sale or distribution of items such as hats and tee shirts with tobacco brands or logos; and
- prohibits brand name sponsorship of any athletic, musical, artistic, or other social or cultural event, or any entry or team in any event.

Subject to the limitations described below, the Final Tobacco Marketing Rule took effect in June 2010. At the time of the re-promulgation of the Final Tobacco Marketing Rule, the FDA also issued an advance notice of proposed rulemaking regarding the so-called “1000 foot rule,” which would establish restrictions on the placement of outdoor tobacco advertising in relation to schools and playgrounds. PM USA and USSTC submitted comments on this advance notice.

Since enactment, several lawsuits have been filed challenging various provisions of the FSPTCA and the Final Tobacco Marketing Rule, including their constitutionality and the scope of the FDA’s authority thereunder. Altria Group, Inc. and its tobacco subsidiaries are not parties to any of these lawsuits. As a result of one such challenge (*Commonwealth Brands*), the portion of the Final Tobacco Marketing Rule that bans the use of color and graphics in labeling and advertising is unenforceable by the FDA. For a further discussion of the Final Tobacco Marketing Rule and the status of graphic warnings for cigarette packages and advertising, see *FDA Regulatory Actions - Graphic Warnings* below.

In a separate challenge to the Final Tobacco Marketing Rule in the U.S. District Court for the Eastern District of Virginia, Renegade Tobacco Company, Inc. and others have challenged the constitutionality of an FDA regulation that restricts tobacco manufacturers from using the trade or brand name of a non-tobacco product on cigarettes or smokeless tobacco products. In May 2010, the district court issued a stay in the Renegade case pending the FDA’s consideration of amendments to the trade or brand name rule. In November 2011, the FDA proposed an amended rule, but continues to exercise its discretion to enforce the original trade or brand name provisions of the Final Tobacco Marketing Rule according to FDA guidance issued in May 2010. The case was dismissed without prejudice in November 2013 pursuant to a stipulation by which the FDA agreed not to enforce the current or any amended trade name rule against plaintiffs until at least 180 days after rulemaking on the amended rule concludes. This relief only applies to plaintiffs in the case. All others are subject to the FDA’s exercise of enforcement discretion pursuant to the May 2010 guidance.

### Contraband

The FSPTCA imposes on manufacturers reporting obligations relating to knowledge of suspected contraband activity involving their brands and also grants the FDA the authority to impose certain recordkeeping and other obligations to address illicit trade in tobacco products. The FSPTCA also empowers the FDA to assess whether additional tools should be employed to track and trace tobacco products through the distribution chain.

### FDA Regulatory Actions

#### Graphic Warnings

In June 2011, as required by the FSPTCA, the FDA issued its final rule to modify the required warnings that appear on cigarette packages and in cigarette advertisements. The FSPTCA requires the warnings to consist of nine new textual warning statements accompanied by color graphics depicting the negative health consequences of smoking. The graphic health warnings will (i) be located beneath the cellophane, and comprise the top 50% of the front and rear panels of cigarette packages and (ii) occupy 20% of a cigarette advertisement and be located at the top of the advertisement. After a legal challenge to the rule initiated by R.J. Reynolds, Lorillard and several other plaintiffs, in which plaintiffs prevailed both at the trial and federal appellate levels, the FDA decided not to seek further review of the U.S. Court of Appeals’ decision and announced its plans to propose a new graphic warnings rule in the future.

#### New Product Marketing Authorization Processes

In January 2011, the FDA issued guidance concerning reports that manufacturers must submit for certain FDA-regulated tobacco products that the manufacturer modified or introduced for the first time into the market after February 15, 2007. These reports must be reviewed by the agency to determine if such tobacco products are “substantially equivalent” to products commercially available as of February 15, 2007. In general, in order to continue marketing these products sold before March 22, 2011, manufacturers of FDA-regulated tobacco products were required to send to the FDA a report demonstrating substantial equivalence by March 22, 2011. PM USA and USSTC submitted timely reports. PM USA and USSTC can continue marketing these products unless the FDA makes a determination that a specific product is not substantially equivalent. If the FDA ultimately makes such a determination, it could require the removal of such products or subject them to the New Product Application Process and, if any such applications are denied, prevent the continued distribution and sale of such products. PM USA and USSTC believe all of their current products meet the statute’s requirements, but cannot predict when or how the FDA will respond to their substantial equivalence reports.

Manufacturers intending to introduce new products and certain modified products into the market after March 22, 2011 must submit a report to the FDA and obtain a “substantial equivalence order” from the agency before introducing the products into the market. If the FDA declines to issue a so-called “substantial equivalence order” for a product or if the manufacturer itself determines that the product does not meet the substantial equivalence requirements, the product would need to undergo the New Product Application Process.

The FDA began announcing its decisions on substantial equivalence reports in the second quarter of 2013. However, there are a significant number of substantial equivalence reports for which the FDA has not announced decisions. At this time, it is not possible to predict how long agency reviews of either substantial equivalence reports or new product applications will take.

#### Good Manufacturing Practices

In March 2013, the FDA published a notice announcing that it had established a public docket to obtain input by May 20, 2013 on the proposed Good Manufacturing Practice Regulations recommended to the FDA in January 2012 by a group of tobacco companies, including PM USA and USSTC. The FSPTCA requires that the FDA promulgate good manufacturing practice regulations for tobacco product manufacturers, but does not specify a timeframe for such regulations.

#### Proposed Deeming Regulations

See *FSPTCA and FDA Regulation - The Regulatory Framework* above for a discussion of the regulations proposed by the FDA in April 2014 that would impose the FSPTCA regulatory framework on machine-made large cigars, e-vapor products such as electronic cigarettes, pipe tobacco and chewable tobacco-derived nicotine products.

### Excise Taxes

Tobacco products are subject to substantial excise taxes in the United States. Significant increases in tobacco-related taxes or fees have been proposed or enacted (including with respect to e-vapor products) and are likely to continue to be proposed or enacted at the federal, state and local levels within the United States.

Federal, state and local excise taxes have increased substantially over the past decade, far outpacing the rate of inflation. For example, in 2009, the federal excise tax (“FET”) on cigarettes increased from $0.39 per pack to approximately $1.01 per pack and in July 2010, the New York state excise tax increased by $1.60 to $4.35 per pack. Between the end of 1998 and July 18, 2014, the weighted-average state and certain local cigarette excise taxes increased from $0.36 to $1.48 per pack. As of July 18, 2014, Vermont is the only state to have enacted a cigarette excise tax increase in 2014. The President’s fiscal year 2014 Budget proposes significant increases in the FET for all tobacco products. The proposed budget would increase the FET on a pack of cigarettes by $0.94 per pack, raising the total FET to $1.95 per pack, and would also increase the tax on other tobacco products by a proportionate amount. It is not possible to predict whether this proposed FET increase will be enacted.

Tax increases are expected to continue to have an adverse impact on sales of the tobacco products of our tobacco subsidiaries through lower consumption levels and the potential shift in adult consumer purchases from the premium to the non-premium or discount segments or to other low-priced or low-taxed tobacco products or to counterfeit and contraband products. Such shifts may have an adverse impact on the reported share performance of tobacco products of Altria Group, Inc.’s tobacco subsidiaries.

A majority of states currently tax smokeless tobacco products using an ad valorem method, which is calculated as a percentage of the price of the product, typically the wholesale price. This ad valorem method results in more tax being paid on premium products than is paid on lower-priced products of equal weight. Altria Group, Inc.’s subsidiaries support legislation to convert ad valorem taxes on smokeless tobacco to a weight-based methodology because, unlike the ad valorem tax, a weight-based tax subjects cans of equal weight to the same tax. As of July 18, 2014, the federal government, 22 states, Puerto Rico, Philadelphia, Pennsylvania and Cook County, Illinois have adopted a weight-based tax methodology for smokeless tobacco.

### International Treaty on Tobacco Control

The World Health Organization’s Framework Convention on Tobacco Control (the “FCTC”) entered into force in February 2005. As of July 18, 2014, 178 countries, as well as the European Community, have become parties to the FCTC. While the United States is a signatory of the FCTC, it is not currently a party to the agreement, as the agreement has not been submitted to, or ratified by, the United States Senate. The FCTC is the first international public health treaty and its objective is to establish a global agenda for tobacco regulation with the purpose of reducing initiation of tobacco use and encouraging cessation. The treaty recommends (and in certain instances, requires) signatory nations to enact legislation that would, among other things: establish specific actions to prevent youth tobacco product use; restrict or eliminate all tobacco product advertising, marketing, promotion and sponsorship; initiate public education campaigns to inform the public about the health consequences of tobacco consumption and exposure to tobacco smoke and the benefits of quitting; implement regulations imposing product testing, disclosure and performance standards; impose health warning requirements on packaging; and adopt measures intended to combat tobacco product smuggling and counterfeit tobacco products, including tracking and tracing of tobacco products through the distribution chain and restrict smoking in public places.

There are a number of proposals currently under consideration by the governing body of the FCTC, some of which call for substantial restrictions on the manufacture, marketing, distribution and sale of tobacco products. In addition, the Protocol to Eliminate Illicit Trade in Tobacco Products (the “Protocol”) was approved by the Conference of Parties to the FCTC in November 2012. It includes provisions related to the tracking and tracing of tobacco products through the distribution chain and numerous other provisions regarding the regulation of the manufacture, distribution and sale of tobacco products. The Protocol has not yet entered into force, but in any event will not apply to the United States until the Senate ratifies the FCTC and until the President signs, and the Senate ratifies, the Protocol. It is not possible to predict the outcome of these proposals or the impact of any FCTC actions on legislation or regulation in the United States, either directly or as a result of the United States becoming a party to the FCTC, or whether or how these actions might indirectly influence FDA regulation and enforcement.

### State Settlement Agreements

As discussed in Note 9, during 1997 and 1998, PM USA and other major domestic tobacco product manufacturers entered into the State Settlement Agreements. These settlements require participating manufacturers to make substantial annual payments, which are adjusted for several factors, including inflation, market share and industry volume. For a discussion of the impact of the State Settlement Agreements, FETRA and FDA user fee payments on Altria Group, Inc., see *Financial Review - Debt and Liquidity - Payments Under State Settlement and Other Tobacco Agreements, and FDA Regulation* below. The State Settlement Agreements also place numerous requirements and restrictions on participating manufacturers’ business operations, including prohibitions and restrictions on the advertising and marketing of cigarettes and smokeless tobacco products. Among these are prohibitions of outdoor and transit brand advertising, payments for product placement and free sampling (except in adult-only facilities). Restrictions are also placed on the use of brand name sponsorships and brand name non-tobacco products. The State Settlement Agreements also place prohibitions on targeting youth and the use of cartoon characters. In addition, the State Settlement Agreements require companies to affirm corporate principles directed at reducing underage use of cigarettes; impose requirements regarding lobbying activities; mandate public disclosure of certain industry documents; limit the industry’s ability to challenge certain tobacco control and underage use laws; and provide for the dissolution of certain tobacco-related organizations and place restrictions on the establishment of any replacement organizations.

In November 1998, USSTC entered into the Smokeless Tobacco Master Settlement Agreement (the “STMSA”) with the attorneys general of various states and United States territories to resolve the remaining health care cost reimbursement cases initiated against USSTC. The STMSA required USSTC to adopt various marketing and advertising restrictions. USSTC is the only smokeless tobacco manufacturer to sign the STMSA.

### Other Federal, State and Local Regulation and Activity

### Federal, State and Local Regulation

A number of states and localities have enacted or proposed legislation that imposes restrictions on tobacco products, such as legislation that (1) prohibits the sale of certain tobacco products with certain characterizing flavors, (2) requires the disclosure of health information separate from or in addition to federally-mandated health warnings, and (3) restricts commercial speech or imposes additional restrictions on the marketing or sale of tobacco products (including proposals to ban all tobacco product sales or to increase the legal age to purchase tobacco products above the current federal minimum age requirement of 18). The legislation varies in terms of the type of tobacco products, the conditions under which such products are or would be restricted or prohibited, and exceptions to the restrictions or prohibitions. For example, a number of proposals involving characterizing flavors would prohibit smokeless tobacco products with characterizing flavors without providing an exception for mint- or wintergreen-flavored products. See *FSPTCA and FDA Regulation* above for a summary of the FSPTCA’s regulation of certain tobacco products with characterizing flavors.

Whether other states or localities will enact legislation in these areas, and the precise nature of such legislation if enacted, cannot be predicted. Altria Group, Inc.’s tobacco subsidiaries have challenged and will continue to challenge certain state and local legislation, including through litigation. For example, in January 2014, PM USA, Middleton and a USSTC subsidiary, along with other tobacco product manufacturers and three trade associations representing New York City retailers, filed a lawsuit in the U.S. District Court for the Southern District of New York challenging the coupon/discount ban included in a recently-enacted New York City ordinance on the grounds that it violates the First Amendment and is preempted by federal and state law. On June 18, 2014, the district court upheld the ordinance.

### Federal Tobacco Quota Buy-Out

In October 2004, FETRA was signed into law. PM USA, Middleton and USSTC are subject to the requirements of FETRA. FETRA eliminated the federal tobacco quota and price support program through an industry-funded buy-out of tobacco growers and quota holders. The cost of the 10-year buy-out, which expires after the third quarter of 2014, is approximately $9.5 billion and is being paid by manufacturers and importers of each kind of tobacco product subject to FET. The cost is being allocated based on the relative market shares of manufacturers and importers of each kind of such tobacco product.

In February 2011, PM USA filed a lawsuit in the U.S. District Court for the Eastern District of Virginia challenging the USDA’s method for calculating the 2011 and future tobacco product class shares that are used to allocate liability for the industry payments that fund the FETRA buy-out described above. PM USA asserted in this litigation that the USDA violated FETRA, and imposed excessive FETRA assessments on PM USA, by failing to apply the most current FET rates enacted by Congress, which became effective in April 2009, in calculating the class share allocations. The Cigar Association of America has joined the litigation as a defendant intervenor. In October 2012, the district court denied PM USA’s motion for summary judgment, granted the defendants’ motion for summary judgment and dismissed the case. In December 2012, PM USA filed a notice of appeal to the U.S. Court of Appeals for the Fourth Circuit. Oral argument was held in September 2013. In November 2013, the Fourth Circuit affirmed the district court’s decision granting summary judgment.

For a discussion of the impact of the State Settlement Agreements, FETRA and FDA user fee payments on Altria Group, Inc., see *Financial Review - Debt and Liquidity - Payments Under State Settlement and Other Tobacco Agreements, and FDA Regulation* below. We do not anticipate that the quota buy-out will have a material adverse impact on our consolidated results in 2014.

### Health Effects of Tobacco Consumption and Exposure to Environmental Tobacco Smoke (“ETS”)

It is the policy of Altria Group, Inc. and its tobacco subsidiaries to defer to the judgment of public health authorities as to the content of warnings in advertisements and on product packaging regarding the health effects of tobacco consumption, addiction and exposure to ETS. Altria Group, Inc. and its tobacco subsidiaries believe that the public should be guided by the messages of the United States Surgeon General and public health authorities worldwide in making decisions concerning the use of tobacco products.

Reports with respect to the health effects of smoking have been publicized for many years, including in a January 2014 United States Surgeon General report titled “The Health Consequences of Smoking - 50 Years of Progress” and in a June 2006 United States Surgeon General report on ETS titled “The Health Consequences of Involuntary Exposure to Tobacco Smoke.”

Most jurisdictions within the United States have restricted smoking in public places. Some public health groups have called for, and various jurisdictions have adopted or proposed, bans on smoking in outdoor places, in private apartments and in cars transporting minors. It is not possible to predict the results of ongoing scientific research or the types of future scientific research into the health risks of tobacco exposure and the impact of such research on regulation.

### Other Legislation or Governmental Initiatives

In addition to the actions discussed above, other regulatory initiatives affecting the tobacco industry have been adopted or are being considered at the federal level and in a number of state and local jurisdictions. For example, in recent years, legislation has been introduced or enacted at the state or local level to subject tobacco products to various reporting requirements and performance standards (such as reduced cigarette ignition propensity standards); establish educational campaigns relating to tobacco consumption or tobacco control programs, or provide additional funding for governmental tobacco control activities; restrict the sale of tobacco products in certain retail establishments and the sale of tobacco products in certain package sizes; require tax stamping of moist smokeless tobacco (“MST”) products; require the use of state tax stamps using data encryption technology; and further restrict the sale, marketing and advertising of cigarettes and other tobacco products. Such legislation may be subject to constitutional or other challenges on various grounds, which may or may not be successful.

It is not possible to predict what, if any, additional legislation, regulation or other governmental action will be enacted or implemented (and, if challenged, upheld) relating to the manufacturing, design, packaging, marketing, advertising, sale or use of tobacco products, or the tobacco industry generally. It is possible, however, that legislation, regulation or other governmental action could be enacted or implemented that might materially adversely affect the business and volume of our tobacco subsidiaries and our consolidated results of operations and cash flows.

### Governmental Investigations

From time to time, Altria Group, Inc. and its subsidiaries are subject to governmental investigations on a range of matters. Altria Group, Inc. and its subsidiaries cannot predict whether new investigations may be commenced.

### Illicit Trade in Tobacco Products

Illicit trade in tobacco products can have an adverse impact on the businesses of Altria Group, Inc. and its tobacco subsidiaries. Illicit trade can take many forms, including the sale of counterfeit tobacco products; the sale of tobacco products in the United States that are intended for sale outside the country; the sale of tobacco products over the Internet and by other means designed to avoid the collection of applicable taxes; and diversion into one taxing jurisdiction of tobacco products intended for sale in another. Counterfeit tobacco products, for example, are manufactured by unknown third parties in unregulated environments. Counterfeit versions of PM USA, USSTC or Middleton products can negatively affect adult tobacco consumer experiences with and opinions of those brands. Illicit trade in tobacco products also harms law-abiding wholesalers and retailers by depriving them of lawful sales and undermines the significant investment Altria Group, Inc.’s tobacco subsidiaries have made in legitimate distribution channels. Moreover, illicit trade in tobacco products results in federal, state and local governments losing tax revenues. Losses in tax revenues can cause such governments to take various actions, including increasing excise taxes; imposing legislative or regulatory requirements that may adversely impact Altria Group, Inc.’s consolidated results of operations and cash flows and the businesses of its tobacco subsidiaries; or asserting claims against manufacturers of tobacco products or members of the trade channels through which such tobacco products are distributed and sold.

Altria Group, Inc. and its tobacco subsidiaries devote significant resources to help prevent illicit trade in tobacco products and to protect legitimate trade channels. For example, Altria Group, Inc.’s tobacco subsidiaries are engaged in a number of initiatives to help prevent illicit trade in tobacco products, including communication with wholesale and retail trade members regarding illicit trade in tobacco products and how they can help prevent such activities; enforcement of wholesale and retail trade programs and policies that address illicit trade in tobacco products; engagement with and support of law enforcement and regulatory agencies; litigation to protect their trademarks; and support for a variety of federal and state legislative initiatives. Legislative initiatives to address illicit trade in tobacco products are designed to protect the legitimate channels of distribution, impose more stringent penalties for the violation of illegal trade laws and provide additional tools for law enforcement. Regulatory measures and related governmental actions to prevent the illicit manufacture and trade of tobacco products continue to evolve as the nature of illicit tobacco products evolves.

### Tobacco Price, Availability and Quality

Shifts in crops driven by economic conditions and adverse weather patterns, government mandated prices and production control programs may increase or decrease the cost or reduce the quality of tobacco and other agricultural products used to manufacture our products. As with other agriculture commodities, the price of tobacco leaf can be influenced by economic conditions and imbalances in supply and demand and crop quality and availability can be influenced by variations in weather patterns, including those caused by climate change. Tobacco production in certain countries is subject to a variety of controls, including government mandated prices and production control programs. Changes in the patterns of demand for agricultural products and the cost of tobacco production could impact tobacco leaf prices and tobacco supply. Any significant change in tobacco leaf prices, quality or availability could affect our tobacco subsidiaries’ profitability and business.

### Timing of Sales

In the ordinary course of business, our tobacco subsidiaries are subject to many influences that can impact the timing of sales to customers, including the timing of holidays and other annual or special events, the timing of promotions, customer incentive programs and customer inventory programs, as well as the actual or speculated timing of pricing actions and tax-driven price increases.

### Operating Results

The following discussion compares operating results for the smokeable and smokeless products segments for the six and three months ended June 30, 2014, with the six and three months ended June 30, 2013.

*(in millions)*

|  | For the Six Months Ended June 30, Net Revenues 2014 | 2013 | Operating Companies Income 2014 | 2013 |
| --- | ---: | ---: | ---: | ---: |
| Smokeable products | $10,569 | $10,646 | $3,320 | $3,646 |
| Smokeless products | 879 | 848 | 524 | 492 |
| Total smokeable and smokeless products | $11,448 | $11,494 | $3,844 | $4,138 |

*(in millions)*

|  | For the Three Months Ended June 30, Net Revenues 2014 | 2013 | Operating Companies Income 2014 | 2013 |
| --- | ---: | ---: | ---: | ---: |
| Smokeable products | $5,611 | $5,678 | $1,789 | $1,726 |
| Smokeless products | 464 | 458 | 285 | 270 |
| Total smokeable and smokeless products | $6,075 | $6,136 | $2,074 | $1,996 |

- 81-

### Smokeable products segment

The smokeable products segment’s operating companies income (which includes higher NPM Adjustment Items for the six months ended June 30, 2013) decreased during the first half of 2014 and increased during the three months ended June 30, 2014 versus the prior-year periods. PM USA grew *Marlboro’*s and its total cigarette category retail share versus both prior-year periods.

The following table summarizes smokeable products segment shipment volume performance:

*(sticks in millions)*

| Cigarettes: | Shipment Volume For the Six Months Ended June 30, 2014 | 2013 | Change | For the Three Months Ended June 30, 2014 | 2013 | Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Marlboro | 52,495 | 54,554 | (3.8)% | 27,679 | 29,119 | (4.9)% |
| Other premium | 3,458 | 3,822 | (9.5)% | 1,829 | 2,040 | (10.3)% |
| Discount | 4,930 | 4,944 | (0.3)% | 2,626 | 2,660 | (1.3)% |
| Total cigarettes | 60,883 | 63,320 | (3.8)% | 32,134 | 33,819 | (5.0)% |
| Cigars: |  |  |  |  |  |  |
| Black & Mild | 590 | 563 | 4.8% | 320 | 294 | 8.8% |
| Other | 15 | 8 | 87.5% | 11 | 4 | 100%+ |
| Total cigars | 605 | 571 | 6.0% | 331 | 298 | 11.1% |
| Total smokeable products | 61,488 | 63,891 | (3.8)% | 32,465 | 34,117 | (4.8)% |

Cigarettes shipment volume includes *Marlboro*; Other premium brands, such as *Virginia Slims, Parliament* and *Benson & Hedges*; and Discount brands, which include *L&M* and *Basic.* Cigarettes volume includes units sold as well as promotional units, but excludes units sold in Puerto Rico and U.S. Territories, to Overseas Military and by Philip Morris Duty Free Inc., none of which, individually or in the aggregate, is material to the smokeable products segment.

The following table summarizes the smokeable products segment retail share performance:

| Cigarettes: | Retail Share For the Six Months Ended June 30, 2014 | 2013 | Percentage Point Change | For the Three Months Ended June 30, 2014 | 2013 | Percentage Point Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Marlboro | 43.8% | 43.7% | 0.1 | 44.0% | 43.7% | 0.3 |
| Other premium | 2.9 | 3.1 | (0.2) | 2.9 | 3.1 | (0.2) |
| Discount | 4.1 | 3.8 | 0.3 | 4.1 | 3.9 | 0.2 |
| Total cigarettes | 50.8% | 50.6% | 0.2 | 51.0% | 50.7% | 0.3 |
| Cigars: |  |  |  |  |  |  |
| Black & Mild | 28.6% | 28.7% | (0.1) | 29.0% | 29.4% | (0.4) |
| Other | 0.3 | 0.2 | 0.1 | 0.4 | 0.2 | 0.2 |
| Total cigars | 28.9% | 28.9% | — | 29.4% | 29.6% | (0.2) |

Retail share results for cigarettes are based on data from IRI/Management Science Associate Inc., a tracking service that uses a sample of stores and certain wholesale shipments to project market share and depict share trends. Retail share results for cigars are based on data from IRI InfoScan, a tracking service that uses a sample of stores to project market share and depict share trends. Both services track sales in the Food, Drug and Mass Merchandisers (including Wal-Mart), Convenience, Military, Dollar Store and Club trade classes. For other trade classes selling cigarettes, retail share is based on shipments from wholesalers to retailers through the Store Tracking Analytical Reporting System (“STARS”). These services are not designed to capture sales through other channels, including the internet, direct mail and some illicitly tax-advantaged outlets. Retail share results for cigars are based on data for machine-made large cigars. Middleton defines machine-made large cigars as cigars made by machine that weigh greater than three pounds per thousand, except cigars sold at retail in packages of 20 cigars. Because the cigars service represents retail share performance only in key trade channels, it should not be considered a precise measurement of actual retail share. It is IRI’s standard practice to periodically refresh its services, which could restate retail share results that were previously released in these services.

PM USA and Middleton executed the following pricing and promotional allowance actions during 2014 and 2013:

- Effective May 11, 2014, PM USA reduced its wholesale promotional allowance on *Marlboro* and *L&M* by $0.06 per pack. In addition, PM USA increased the list price on all of its other cigarette brands by $0.06 per pack, except for *Parliament*, which PM USA increased by $0.11 per pack.
- Effective December 1, 2013, PM USA reduced its wholesale promotional allowance on *Marlboro* and *L&M* by $0.07 per pack. In addition, PM USA increased the list price on all of its other cigarette brands by $0.07 per pack.
- Effective June 10, 2013, PM USA reduced its wholesale promotional allowance on *Marlboro* and *L&M* by $0.06 per pack. In addition, PM USA increased the list price on all of its other cigarette brands by $0.06 per pack.

Net revenues, which include excise taxes billed to customers, for the six months ended June 30, 2014, decreased $77 million (0.7%), due primarily to lower shipment volume ($453 million), partially offset by higher pricing, which includes higher promotional investments. Operating companies income for the six months ended June 30, 2014 decreased $326 million (8.9%), due primarily to higher NPM Adjustment Items in 2013 ($476 million) and lower shipment volume ($226 million), partially offset by higher pricing, which includes higher promotional investments.

Net revenues, which include excise taxes billed to customers, for the three months ended June 30, 2014, decreased $67 million (1.2%) as lower shipment volume ($304 million) was partially offset by higher pricing. Operating companies income for the three months ended June 30, 2014 increased $63 million (3.7%), due primarily to higher pricing, partially offset by lower shipment volume ($152 million) and higher per unit settlement charges.

Total smokeable products shipment volume for the six and three months ended June 30, 2014 decreased 3.8% and 4.8%, respectively, versus the prior-year periods.

PM USA’s reported domestic cigarettes shipment volume decreased 3.8% for the six months ended June 30, 2014, due primarily to the industry’s decline, partially offset by retail share gains. PM USA’s reported domestic cigarettes shipment volume decreased 5.0% for the three months ended June 30, 2014, driven by the industry’s decline and wholesale inventory reductions in the second quarter of 2014, following elevated inventory levels in the first quarter of 2014. When adjusted for trade inventory changes and other factors, PM USA estimates that its first-half and second quarter 2014 domestic cigarettes shipment volume decreased approximately 4%. PM USA estimates total industry cigarette volumes declined approximately 4.5% in both periods.

PM USA’s shipments of premium cigarettes accounted for 91.9% and 91.8% of its reported domestic cigarettes shipment volume for the six and three months ended June 30, 2014, respectively, versus 92.2% and 92.1%, for the six and three months ended June 30, 2013, respectively.

Middleton’s reported cigars shipment volume for the first half and second quarter of 2014 increased 6.0% and 11.1%, respectively, driven by *Black & Mild’*s performance in the tipped cigars segment and the expansion of *Royal Comfort* untipped cigarillos in select geographies.

*Marlboro’*s retail share for the first half and second quarter of 2014 increased 0.1 and 0.3 share points, respectively, versus the prior-year periods.

PM USA’s first-half and second quarter of 2014 retail share increased 0.2 and 0.3 share points, respectively, versus the prior-year periods, due to retail share gains by *Marlboro*, and by *L&M* in Discount, partially offset by share losses on other portfolio brands.

In the machine-made large cigars category, *Black & Mild’*s retail share decreased 0.1 and 0.4 share points in the first half and second quarter of 2014, respectively, compared to the prior-year periods.

### Smokeless products segment

In both the first half and second quarter of 2014, USSTC and PM USA grew operating companies income and expanded operating companies income margins versus the prior-year periods. USSTC also increased *Copenhagen* and *Skoal’*s combined volume and retail share during the six and three months ended June 30, 2014 versus the prior-year periods.

The following table summarizes smokeless products segment shipment volume performance:

*(cans and packs in millions)*

|  | Shipment Volume For the Six Months Ended June 30, 2014 | 2013 | Change | For the Three Months Ended June 30, 2014 | 2013 | Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Copenhagen | 218.9 | 200.2 | 9.3% | 115.0 | 106.7 | 7.8% |
| Skoal | 133.3 | 138.2 | (3.5)% | 69.3 | 73.8 | (6.1)% |
| Copenhagen and Skoal | 352.2 | 338.4 | 4.1% | 184.3 | 180.5 | 2.1% |
| Other | 37.7 | 37.8 | (0.3)% | 19.5 | 20.0 | (2.5)% |
| Total smokeless products | 389.9 | 376.2 | 3.6% | 203.8 | 200.5 | 1.6% |

Smokeless products shipment volume includes cans and packs sold, as well as promotional units, but excludes international volume, which is not material to the smokeless products segment. Other includes certain USSTC and PM USA smokeless products. New types of smokeless products, as well as new packaging configurations of existing smokeless products, may or may not be equivalent to existing MST products on a can-for-can basis. To calculate volumes of cans and packs shipped, USSTC and PM USA have assumed that one pack of snus, irrespective of the number of pouches in the pack, is equivalent to one can of MST.

The following table summarizes smokeless products segment retail share performance (excluding international volume):

|  | Retail Share For the Six Months Ended June 30, 2014 | 2013 | Percentage Point Change | For the Three Months Ended June 30, 2014 | 2013 | Percentage Point Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Copenhagen | 30.4% | 28.9% | 1.5 | 30.5% | 29.0% | 1.5 |
| Skoal | 20.6 | 21.8 | (1.2) | 20.6 | 21.7 | (1.1) |
| Copenhagen and Skoal | 51.0 | 50.7 | 0.3 | 51.1 | 50.7 | 0.4 |
| Other | 4.0 | 4.3 | (0.3) | 4.0 | 4.3 | (0.3) |
| Total smokeless products | 55.0% | 55.0% | — | 55.1% | 55.0% | 0.1 |

Retail share results for smokeless products are based on data from IRI InfoScan, a tracking service that uses a sample of stores to project market share and depict share trends. The service tracks sales in the Food, Drug and Mass Merchandisers (including Wal-Mart), Convenience, Military, Dollar Store and Club trade classes on the number of cans and packs sold. Smokeless products is defined by IRI as moist smokeless and spit-free tobacco products. Other includes certain USSTC and PM USA smokeless products. New types of smokeless products, as well as new packaging configurations of existing smokeless products, may or may not be equivalent to existing MST products on a can-for-can basis. USSTC and PM USA have assumed that one pack of snus, irrespective of the number of pouches in the pack, is equivalent to one can of MST. All other products are considered to be equivalent on a can-for-can basis. Because this service represents retail share performance only in key trade channels, it should not be considered a precise measurement of actual retail share. It is IRI’s standard practice to periodically refresh its InfoScan services, which could restate retail share results that were previously released in this service.

USSTC and PM USA executed the following pricing actions during 2014 and 2013:

- Effective May 11, 2014, USSTC increased the list price on all of its brands by $0.06 per can.
- Effective May 11, 2014, PM USA increased the list price on *Marlboro* Snus tins and flip-top box (“FTB”) by $0.06 per tin or FTB.
- Effective December 8, 2013, USSTC increased the list price on all of its brands by $0.06 per can.
- Effective December 1, 2013, PM USA increased the list price on *Marlboro* Snus tins and FTB by $0.06 per tin or FTB.
- Effective May 13, 2013, PM USA increased the list price on *Marlboro* Snus tins and FTB by $0.05 per tin or FTB.
- Effective May 12, 2013, USSTC increased the list price on all of its brands by $0.05 per can.

Net revenues, which include excise taxes billed to customers, for the six and three months ended June 30, 2014 increased $31 million (3.7%) and $6 million (1.3%), respectively, versus the prior-year periods, due primarily to higher volume and higher pricing, which includes higher promotional investments. Operating companies income for the six and three months ended June 30, 2014 increased $32 million (6.5%) and $15 million (5.6%), respectively, versus the prior-year periods, due primarily to higher pricing, which includes higher promotional investments, and higher shipment volume.

For the six and three months ended June 30, 2014, USSTC and PM USA’s combined reported domestic smokeless products shipment volume increased 3.6% and 1.6%, respectively, as volume growth in *Copenhagen* was partially offset by volume declines in *Skoal* and Other portfolio brands.

*Copenhagen* and *Skoal’*s combined reported shipment volume for the first half and second quarter of 2014 increased 4.1% and 2.1%, respectively, versus the prior-year periods.

For both the first half of 2014 and the second quarter of 2014, trade inventory movements related to changes in *Skoal’*s promotional strategy negatively affected volume performance. After adjusting for calendar differences and trade inventory changes, USSTC and PM USA estimate that their combined domestic smokeless products shipment volume grew approximately 3.5% in both the first half and second quarter of 2014, while smokeless products category volume grew approximately 4.5% over the 12 months ended June 30, 2014.

*Copenhagen* and *Skoal’*s combined retail share increased 0.3 and 0.4 share points in the first half and second quarter of 2014, respectively. *Copenhagen’*s retail share increased 1.5 share points in both the first half and second quarter of 2014, driven primarily by *Copenhagen* Long Cut Wintergreen. For the first-half of 2014, *Skoal’*s retail share declined 1.2 share points. *Skoal’*s retail share declined 1.1 share points in the second quarter of 2014, while its sequential retail share was unchanged.

USSTC and PM USA’s combined smokeless products retail share for the first half of 2014 was unchanged. USSTC and PM USA’s combined smokeless products retail share for the second quarter of 2014 increased 0.1 share point, as retail share gains for *Copenhagen* were mostly offset by share losses for *Skoal* and Other portfolio brands.

### Wine segment

### Business Environment

Ste. Michelle is a leading producer of Washington state wines, primarily *Chateau Ste. Michelle, Columbia Crest* and *14 Hands*, and owns wineries in or distributes wines from several other wine regions and foreign countries. Ste. Michelle holds an 85% ownership interest in Michelle-Antinori, LLC, which owns *Stag’s Leap Wine Cellars* in Napa Valley. Ste. Michelle also owns *Conn Creek* in Napa Valley and *Erath* in Oregon. In addition, Ste. Michelle imports and markets *Antinori, Torres* and *Villa Maria Estate* wines and *Champagne Nicolas Feuillatte* in the United States. Key elements of Ste. Michelle’s strategy are expanded domestic distribution of its wines, especially in certain account categories such as restaurants, wholesale clubs, supermarkets, wine shops and mass merchandisers, and a focus on improving product mix to higher-priced, premium products.

Ste. Michelle’s business is subject to significant competition, including competition from many larger, well-established domestic and international companies, as well as from many smaller wine producers. Wine segment competition is primarily based on quality, price, consumer and trade wine tastings, competitive wine judging, third-party acclaim and advertising. Substantially all of Ste. Michelle’s sales occur through state-licensed distributors.

Federal, state and local governmental agencies regulate the alcohol beverage industry through various means, including licensing requirements, pricing, labeling and advertising restrictions, and distribution and production policies. Further regulatory restrictions or additional excise or other taxes on the manufacture and sale of alcoholic beverages may have an adverse effect on Ste. Michelle’s wine business.

### Operating Results

Ste. Michelle increased its net revenues and operating companies income for the first half and second quarter of 2014, due primarily to higher pricing and higher shipment volume.

The following discussion compares wine segment results for the six and three months ended June 30, 2014, with the six and three months ended June 30, 2013.

*(in millions)*

|  | For the Six Months Ended June 30, 2014 | 2013 | For the Three Months Ended June 30, 2014 | 2013 |
| --- | ---: | ---: | ---: | ---: |
| Net revenues | $275 | $263 | $146 | $137 |
| Operating companies income | $50 | $45 | $28 | $25 |

The following table summarizes wine segment case shipment volume performance:

*(cases in thousands)*

|  | Shipment Volume For the Six Months Ended June 30, 2014 | 2013 | Change | For the Three Months Ended June 30, 2014 | 2013 | Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Chateau Ste. Michelle | 1,304 | 1,184 | 10.1% | 731 | 654 | 11.8% |
| Columbia Crest 1 | 378 | 452 | (16.4)% | 186 | 225 | (17.3)% |
| 14 Hands | 757 | 653 | 15.9% | 371 | 336 | 10.4% |
| Other 1 | 1,151 | 1,247 | (7.7)% | 599 | 636 | (5.8)% |
| Total wine | 3,590 | 3,536 | 1.5% | 1,887 | 1,851 | 1.9% |
| 1 Two Vines is no longer sold under the Columbia Crest brand. Effective January 1, 2014, shipment volume for Two Vines is included in “Other.” Prior-period shipment volume for Columbia Crest and Other have been adjusted to reflect this change. |  |  |  |  |  |  |

Net revenues, which include excise taxes billed to customers, for the six and three months ended June 30, 2014, increased $12 million (4.6%) and $9 million (6.6%), respectively, versus the prior-year periods, due primarily to higher pricing and higher shipment volume. Operating companies income for the six and three months ended June 30, 2014 increased $5 million (11.1%) and $3 million (12.0%), respectively, versus the prior-year periods, due primarily to higher pricing and higher shipment volume, partially offset by higher costs.

For the the six and three months ended June 30, 2014, Ste. Michelle’s reported wine shipment volume grew 1.5% and 1.9%, respectively, versus the prior-year periods as increased volume of *Chateau Ste. Michelle* and *14 Hands* was mostly offset by declines in *Columbia Crest* and Other brands.

### Financial Review

#### Net Cash Provided by Operating Activities

During the first six months of 2014, net cash provided by operating activities was $759 million compared with $441 million during the first six months of 2013. This increase was due primarily to the following:

- a voluntary $350 million contribution to Altria Group, Inc.’s pension plans during the six months ended June 30, 2013; and
- the timing of payments related to accounts payable and other working capital requirements;

partially offset by:

- higher settlement payments during 2014, driven primarily by the impact of higher NPM Adjustment Items in 2013.

Altria Group, Inc. had a working capital deficit at June 30, 2014 and December 31, 2013. Altria Group, Inc.’s management believes that it has the ability to fund these working capital deficits with cash provided by operating activities and/or short-term borrowings under its commercial paper program as discussed in the *Debt and Liquidity* section below.

#### Net Cash Provided by Investing Activities

During the first six months of 2014, net cash provided by investing activities was $102 million compared with $239 million during the first six months of 2013. This decrease was due primarily to the following:

- Nu Mark’s acquisition of Green Smoke during the second quarter of 2014; and
- lower proceeds from asset sales in the financial services business during the first six months of 2014;

partially offset by:

- the sale of PM USA’s Cabarrus, North Carolina manufacturing facility during the second quarter of 2014.

#### Net Cash Used in Financing Activities

During the first six months of 2014, net cash used in financing activities was $2,843 million compared with $1,009 million during the first six months of 2013. This increase was due primarily to the following:

- debt issuances during the first six months of 2013;
- $525 million repayment of Altria Group, Inc. senior unsecured notes at scheduled maturity during the first six months of 2014;
- higher share repurchases during the first six months of 2014; and
- higher dividends paid during the first six months of 2014.

#### Debt and Liquidity

*Credit Ratings* - Altria Group, Inc.’s cost and terms of financing and its access to commercial paper markets may be impacted by applicable credit ratings. Under the terms of certain of Altria Group, Inc.’s existing debt instruments, a change in a credit rating could result in an increase or a decrease of the cost of borrowings. For instance, the interest rate payable on certain of Altria Group, Inc.’s outstanding notes is subject to adjustment from time to time if the rating assigned to the notes of such series by Moody’s Investors Service, Inc. (“Moody’s”) or Standard & Poor’s Ratings Services (“Standard & Poor’s”) is downgraded (or subsequently upgraded) as and to the extent set forth in the notes. The impact of credit ratings on the cost of borrowings under Altria Group, Inc.’s credit agreement is discussed below.

At June 30, 2014, the credit ratings and outlook for Altria Group, Inc.’s indebtedness by major credit rating agencies were:

|  | Short-term Debt | Long-term Debt | Outlook |
| --- | --- | --- | --- |
| Moody’s | P-2 | Baa1 | Stable |
| Standard & Poor’s 1 | A-2 | BBB+ | Stable |
| Fitch | F2 | BBB+ | Stable |

1 On March 12, 2014, Standard & Poor’s raised the long-term debt credit rating for Altria Group, Inc. to “BBB+” from “BBB”.

*Credit Lines* - From time to time, Altria Group, Inc. has short-term borrowing needs to meet its working capital requirements and generally uses its commercial paper program to meet those needs. At June 30, 2014 and 2013, and at December 31, 2013, there were no short-term borrowings outstanding.

For the six and three months ended June 30, 2014 and 2013, Altria Group, Inc.’s average daily short-term borrowings, peak short-term borrowings outstanding and weighted-average interest rate on short-term borrowings were as follows:

*(dollars in millions)*

|  | For the Six Months Ended June 30, 2014 | 2013 | For the Three Months Ended June 30, 2014 | 2013 |
| --- | ---: | ---: | ---: | ---: |
| Average daily short-term borrowings | $71 | $74 | $142 | $148 |
| Peak short-term borrowings outstanding | $650 | $650 | $650 | $650 |
| Weighted-average interest rate on short-term borrowings | 0.27% | 0.34% | 0.27% | 0.34% |

Short-term borrowings were repaid with cash provided by operating activities. Peak borrowings for the six and three months ended June 30, 2014 and 2013 were due primarily to payments related to State Settlement Agreements as further discussed in *Payments Under State Settlement and Other Tobacco Agreements, and FDA Regulation, Tobacco Space - Business Environment* and Note 9.

At June 30, 2014, Altria Group, Inc. had in place a senior unsecured 5-year revolving credit agreement (the “Credit Agreement”). The Credit Agreement provides for borrowings up to an aggregate principal amount of $3.0 billion and expires on August 19, 2018, with an option, subject to certain conditions, for Altria Group, Inc. to extend the expiration date for two additional one-year periods. Pricing for interest and fees under the Credit Agreement may be modified in the event of a change in the rating of Altria Group, Inc.’s long-term senior unsecured debt. Interest rates on borrowings under the Credit Agreement are expected to be based on the London Interbank Offered Rate (“LIBOR”) plus a percentage based on the higher of the ratings of Altria Group, Inc.’s long-term senior unsecured debt from Standard & Poor’s and Moody’s. The applicable percentage based on Altria Group, Inc.’s long-term senior unsecured debt ratings at June 30, 2014 for borrowings under the Credit Agreement was 1.25%. The Credit Agreement does not include any other rating triggers, nor does it contain any provisions that could require the posting of collateral. At June 30, 2014, credit available to Altria Group, Inc. under the Credit Agreement was $3.0 billion.

The Credit Agreement is used for general corporate purposes and to support Altria Group, Inc.’s commercial paper issuances. The Credit Agreement requires that Altria Group, Inc. maintain (i) a ratio of debt to consolidated earnings before interest, taxes, depreciation and amortization (“EBITDA”) of not more than 3.0 to 1.0 and (ii) a ratio of consolidated EBITDA to consolidated interest expense of not less than 4.0 to 1.0, each calculated as of the end of the applicable quarter on a rolling four quarters basis. At June 30, 2014, the ratios of debt to consolidated EBITDA and consolidated EBITDA to consolidated interest expense, calculated in accordance with the Credit Agreement, were 1.7 to 1.0 and 8.7 to 1.0, respectively. Altria Group, Inc. expects to continue to meet its covenants associated with the Credit Agreement. The terms “consolidated EBITDA,” “debt” and “consolidated interest expense,” as defined in the Credit Agreement, include certain adjustments. Exhibit 99.3 to Altria Group, Inc.’s Form 10-Q for the period ended September 30, 2013 sets forth the definitions of these terms as they appear in the Credit Agreement and is incorporated herein by reference.

Any commercial paper issued by Altria Group, Inc. and borrowings under the Credit Agreement are guaranteed by PM USA as further discussed in Note 10. *Condensed Consolidating Financial Information* to the condensed consolidated financial statements in Item 1 (“Note 10”).

*Financial Market Environment* - Altria Group, Inc. believes it has adequate liquidity and access to financial resources to meet its anticipated obligations and ongoing business needs in the foreseeable future. Altria Group, Inc. continues to monitor the credit quality of its bank group and is not aware of any potential non-performing credit provider in that group. Altria Group, Inc. believes the lenders in its bank group will be willing and able to advance funds in accordance with their legal obligations.

*Debt* - At June 30, 2014 and December 31, 2013, Altria Group, Inc.’s total debt was $14.0 billion and $14.5 billion, respectively.

During the first quarter of 2014, Altria Group, Inc. repaid in full at maturity senior unsecured notes in the aggregate principal amount of $525 million.

*Guarantees and Other Similar Matters* - As discussed in Note 9, at June 30, 2014, Altria Group, Inc. and certain of its subsidiaries had unused letters of credit, guarantees (including third-party guarantees) and a redeemable noncontrolling interest outstanding. From time to time, subsidiaries of Altria Group, Inc. also issue lines of credit to affiliated entities. In addition, as discussed in Note 10, PM USA has issued guarantees related to Altria Group, Inc.’s obligations under its outstanding debt securities, borrowings under the Credit Agreement and amounts outstanding under its commercial paper program. These items have not had, and are not expected to have, a significant impact on Altria Group, Inc.’s liquidity.

*Payments Under State Settlement and Other Tobacco Agreements, and FDA Regulation* - As discussed previously and in Note 9, PM USA has entered into State Settlement Agreements with the states and territories of the United States. PM USA also entered into a trust agreement to provide certain aid to U.S. tobacco growers and quota holders, but PM USA’s obligations under this trust expired on December 15, 2010 (these obligations had been offset by the obligations imposed on PM USA by FETRA, which expires after the third quarter of 2014). USSTC and Middleton are also subject to obligations imposed by FETRA. In addition, in June 2009, PM USA and a subsidiary of USSTC became subject to quarterly user fees imposed by the FDA as a result of the FSPTCA. The State Settlement Agreements, FETRA and the FDA user fees call for payments that are based on variable factors, such as volume, market share and inflation, depending on the subject payment. Altria Group, Inc.’s subsidiaries account for the cost of the State Settlement Agreements, FETRA and FDA user fees as a component of cost of sales. As a result of the State Settlement Agreements, FETRA and FDA user fees, Altria Group, Inc.’s subsidiaries recorded approximately $2.4 billion and $2.0 billion of charges to cost of sales for the six months ended June 30, 2014 and 2013, respectively, and approximately $1.3 billion of charges to cost of sales for the three month periods ended June 30, 2014 and 2013. The 2014 amounts included reductions to cost of sales of $43 million for the six and three months ended June 30, 2014 for the NPM Adjustment Items. The 2013 amounts included reductions to cost of sales of $519 million and $36 million for the six and three months ended June 30, 2013, respectively, for the NPM Adjustment Items.

In connection with the settlement of the NPM Adjustment disputes under the MSA for the years 2003 - 2012, the formula for allocating the revised NPM Adjustments applicable to the signatory states for 2013 and subsequent years among the tobacco product manufacturers that are original signatories to the MSA (“OPMs”) has been modified in a manner favorable to PM USA, although the extent to which it remains favorable to PM USA will depend upon certain future events, including the future relative market shares of the OPMs. For a detailed discussion of settlements of, and determinations made in connection with disputes with certain states related to the NPM Adjustment provision under the MSA for the years 2003 - 2012, see *Health Care Cost Recovery Litigation - Possible Adjustments in MSA Payments for 2003 - 2013* in Note 9.

Based on current agreements, 2013 market share and historical annual industry volume decline rates, the estimated amounts that Altria Group, Inc.’s subsidiaries may charge to cost of sales for payments related to State Settlement Agreements, FETRA and FDA user fees approximate $5 billion in 2014 and $4.6 billion each year thereafter. These amounts reflect the expiration of obligations imposed by FETRA after the third quarter of 2014, which will result in a decrease in the charge to cost of sales of approximately $100 million in 2014 and approximately $400 million starting in 2015. These amounts exclude the potential impact of the revised and streamlined NPM Adjustment provision applicable to signatory states for years after 2014 discussed above and also exclude the adjustments described below.

The estimated amounts due under the State Settlement Agreements and FETRA charged to cost of sales in each year would generally be paid in the following year. The amounts charged to cost of sales for FDA user fees are generally paid in the quarter in which the fees are incurred. As previously stated, the payments due under the terms of the State Settlement Agreements, FETRA and FDA user fees are subject to adjustment for several factors, including volume, inflation and certain contingent events and, in general, are allocated based on each manufacturer’s market share. The future payment amounts discussed above are estimates, and actual payment amounts will differ to the extent underlying assumptions differ from actual future results.

*Litigation Escrow Deposits* - With respect to certain adverse verdicts currently on appeal, to obtain stays of judgments pending appeals, as of June 30, 2014, PM USA had posted various forms of security totaling approximately $42 million, the majority of which has been collateralized with cash deposits. These cash deposits are included in other assets on the condensed consolidated balance sheet.

Although litigation is subject to uncertainty and an adverse outcome or settlement of litigation could have a material adverse effect on the financial position, cash flows or results of operations of PM USA, UST or Altria Group, Inc. in a particular fiscal quarter or fiscal year, as more fully disclosed in Note 9 and in *Cautionary Factors That May Affect Future Results* management expects cash flow from operations, together with Altria Group, Inc.’s access to capital markets, to provide sufficient liquidity to meet ongoing business needs.

*Leases* - PMCC’s investment in leases is included in the line item finance assets, net, on Altria Group, Inc.’s condensed consolidated balance sheets as of June 30, 2014 and December 31, 2013. At June 30, 2014, PMCC’s net finance receivables of approximately $1.7 billion in leveraged leases, which are included in finance assets, net, on Altria Group, Inc.’s condensed consolidated balance sheet, consisted of rents receivable ($3.5 billion) and the residual value of assets under lease ($0.9 billion), reduced by third-party nonrecourse debt ($2.2 billion) and unearned income ($0.5 billion). The repayment of the nonrecourse debt is collateralized by lease payments receivable and the leased property, and is nonrecourse to the general assets of PMCC. As required by U.S. GAAP, the third-party nonrecourse debt has been offset against the related rents receivable and has been presented on a net basis within finance assets, net, on Altria Group, Inc.’s condensed consolidated balance sheets. Finance assets, net, of $1.8 billion at June 30, 2014, also included net finance receivables for direct finance leases and an allowance for losses.

#### Equity and Dividends

On January 28, 2014, Altria Group, Inc. granted an aggregate of 1.4 million shares of restricted and deferred stock to eligible employees. Restrictions on these shares lapse in the first quarter of 2017. The market value per share was $36.73 on the date of grant.

During the six months ended June 30, 2014, 1.6 million shares of restricted and deferred stock vested. The total fair value of restricted and deferred stock that vested during the six months ended June 30, 2014 was $55 million. The weighted-average grant date fair value per share of these awards was $24.36.

Dividends paid during the first six months of 2014 and 2013 were $1,912 million and $1,769 million, respectively, an increase of 8.1%, reflecting a higher dividend rate, partially offset by fewer shares outstanding as a result of shares repurchased by Altria Group, Inc. under its share repurchase programs discussed below. Altria Group, Inc. expects to continue to maintain a dividend payout ratio target of approximately 80% of its adjusted diluted EPS. The current annualized dividend rate is $1.92 per Altria Group, Inc. common share. Future dividend payments remain subject to the discretion of Altria Group, Inc.’s Board of Directors (the “Board of Directors”).

Altria Group, Inc.’s share repurchase activity was as follows:

*(in millions, except per share data)*

|  | For the Six Months Ended June 30, 2014 | 2013 | For the Three Months Ended June 30, 2014 | 2013 |
| --- | ---: | ---: | ---: | ---: |
| Total number of shares repurchased | 10.8 | 5.4 | 3.3 | 3.7 |
| Aggregate cost of shares repurchased | $404 | $192 | $132 | $135 |
| Average price per share of shares repurchased | $37.40 | $35.58 | $40.72 | $36.27 |

At June 30, 2014, Altria Group, Inc. had approximately $53 million remaining in its current $1.0 billion share repurchase program, which it expects to complete by the end of the third quarter of 2014. In July 2014, the Board of Directors authorized a new $1.0 billion share repurchase program (the “July 2014 share repurchase program”) that Altria Group, Inc. intends to commence upon the completion of its current share repurchase program. Altria Group, Inc. expects to complete the July 2014 share repurchase program by the end of 2015. The timing of share repurchases under Altria Group, Inc.’s share repurchase programs depends upon marketplace conditions and other factors, and the programs remain subject to the discretion of the Board of Directors.

For further discussion of Altria Group, Inc.’s share repurchase programs, see Note 1. *Background and Basis of Presentation* to the condensed consolidated financial statements in Item 1.

#### Recent Accounting Guidance Not Yet Adopted

See Note 11. *Recent Accounting Guidance Not Yet Adopted* to the condensed consolidated financial statements in Item 1 for a discussion of recent accounting guidance issued but not yet adopted.

#### Contingencies

See Note 9 for a discussion of contingencies.

### Cautionary Factors That May Affect Future Results

#### Forward-Looking and Cautionary Statements

We (1) may from time to time make written or oral forward-looking statements, including earnings guidance and other statements contained in filings with the SEC, reports to security holders and press releases and investor webcasts. You can identify these forward-looking statements by use of words such as “strategy,” “expects,” “continues,” “plans,” “anticipates,” “believes,” “will,” “estimates,” “forecasts,” “intends,” “projects,” “goals,” “objectives,” “guidance,” “targets” and other words of similar meaning. You can also identify them by the fact that they do not relate strictly to historical or current facts.

We cannot guarantee that any forward-looking statement will be realized, although we believe we have been prudent in our plans and assumptions. Achievement of future results is subject to risks, uncertainties and assumptions that may prove to be inaccurate. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results could vary materially from those anticipated, estimated or projected. You should bear this in mind as you consider forward-looking statements and whether to invest in or remain invested in Altria Group, Inc.’s securities. In connection with the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, we are identifying important factors that, individually or in the aggregate, could cause actual results and outcomes to differ materially from those contained in any forward-looking statements made by us; any such statement is qualified by reference to the following cautionary statements. We elaborate on these and other risks we face throughout this Form 10-Q, particularly in the “Business Environment” sections preceding our discussion of operating results of our subsidiaries’ businesses above. You should understand that it is not possible to predict or identify all risk factors. Consequently, you should not consider the following to be a complete discussion of all potential risks or uncertainties. We do not undertake to update any forward-looking statement that we may make from time to time except as required by applicable law.

**Unfavorable litigation outcomes could materially adversely affect the consolidated results of operations, cash flows or financial position of Altria Group, Inc., or the businesses of one or more of its subsidiaries.**

Legal proceedings covering a wide range of matters are pending or threatened in various United States and foreign jurisdictions against Altria Group, Inc. and its subsidiaries, including PM USA and UST and its subsidiaries, as well as their respective indemnitees. Various types of claims may be raised in these proceedings, including product liability, consumer protection, antitrust, tax, contraband-related claims, patent infringement, employment matters, claims for contribution and claims of competitors and distributors.

Litigation is subject to uncertainty and it is possible that there could be adverse developments in pending or future cases. An unfavorable outcome or settlement of pending tobacco-related or other litigation could encourage the commencement of additional litigation. Damages claimed in some tobacco-related or other litigation are significant and, in certain cases, range in the billions of dollars. The variability in pleadings in multiple jurisdictions, together with the actual experience of management in litigating claims, demonstrate that the monetary relief that may be specified in a lawsuit bears little relevance to the ultimate outcome. In certain cases, plaintiffs claim that defendants’ liability is joint and several. In such cases, Altria Group, Inc. or its subsidiaries may face the risk that one or more co-defendants decline or otherwise fail to participate in the bonding required for an appeal or to pay their proportionate or jury-allocated share of a judgment. As a result, Altria Group, Inc. or its subsidiaries under certain circumstances may have to pay more than their proportionate share of any bonding- or judgment-related amounts. Furthermore, in those cases where plaintiffs are successful, Altria Group, Inc. or its subsidiaries may also be required to pay interest and attorneys’ fees.

Although PM USA has historically been able to obtain required bonds or relief from bonding requirements in order to prevent plaintiffs from seeking to collect judgments while adverse verdicts have been appealed, there remains a risk that such relief may not be obtainable in all cases. This risk has been substantially reduced given that 45 states and Puerto Rico now limit the dollar amount of bonds or require no bond at all. As discussed in Note 9, tobacco litigation plaintiffs have challenged the constitutionality of Florida’s bond cap statute in several cases and plaintiffs may challenge state bond cap statutes in other jurisdictions as well. Such challenges may include the applicability of state bond caps in federal court. Although we cannot predict the outcome of such challenges, it is possible that the consolidated results of operations, cash flows or financial position of Altria Group, Inc., or the businesses of one or more of its subsidiaries, could be materially adversely affected in a particular fiscal quarter or fiscal year by an unfavorable outcome of one or more such challenges.

In certain litigation, PM USA faces potentially significant non-monetary remedies. For example, in the lawsuit brought by the United States Department of Justice, discussed in Note 9, the district court did not impose monetary penalties but ordered significant non-monetary remedies, including the issuance of “corrective statements” in various media.

*1 This section uses the terms “we,” “our” and “us” when it is not necessary to distinguish among Altria Group, Inc. and its various operating subsidiaries or when any distinction is clear from the context.*

Altria Group, Inc. and its subsidiaries have achieved substantial success in managing litigation. Nevertheless, litigation is subject to uncertainty and significant challenges remain.

It is possible that the consolidated results of operations, cash flows or financial position of Altria Group, Inc., or the businesses of one or more of its subsidiaries, could be materially adversely affected in a particular fiscal quarter or fiscal year by an unfavorable outcome or settlement of certain pending litigation. Altria Group, Inc. and each of its subsidiaries named as a defendant believe, and each has been so advised by counsel handling the respective cases, that it has valid defenses to the litigation pending against it, as well as valid bases for appeal of adverse verdicts. Each of the companies has defended, and will continue to defend, vigorously against litigation challenges. However, Altria Group, Inc. and its subsidiaries may enter into settlement discussions in particular cases if they believe it is in the best interests of Altria Group, Inc. to do so. See Note 9 and Exhibits 99.1 and 99.2 to this Form 10-Q for a discussion of pending tobacco-related litigation.

**Altria Group, Inc.’s tobacco subsidiaries are subject to significant governmental and private sector actions intended to reduce or prevent tobacco use, which, together with the diminishing social acceptance of smoking, have resulted, and are expected to continue to result, in reduced cigarette industry volume.**

Our tobacco subsidiaries face significant governmental and private sector action, including efforts aimed at reducing the incidence of tobacco use; restricting marketing and advertising; imposing regulations on packaging; requiring warnings and disclosure of flavors or other ingredients; prohibiting the sale of tobacco products with certain characterizing flavors or other characteristics; requiring pre-market authorization of certain tobacco products; limiting or prohibiting the sale of tobacco products by certain retail establishments and the sale of tobacco products in certain package sizes; and efforts seeking to hold them responsible for the adverse health effects associated with both smoking and exposure to environmental tobacco smoke.

PM USA, USSTC and other Altria Group, Inc. subsidiaries are subject to regulation, and may become subject to additional regulation, by the FDA, as discussed in detail in *Tobacco Space - Business Environment - FSPTCA and FDA Regulation* above. We cannot predict how the FDA will implement and enforce its statutory authority, including by promulgating additional regulations, taking other regulatory actions and pursuing possible investigatory or enforcement actions.

Governmental actions, combined with the diminishing social acceptance of smoking and private actions to restrict smoking, have resulted in reduced cigarette industry volume, and we expect that these factors will continue to reduce cigarette consumption levels. Actions by the FDA, other federal, state or local governments or agencies and private sector entities, such as those which impact the consumer acceptability of tobacco products, limit adult consumer choices, delay or prevent the launch of new or modified tobacco products, restrict communications to adult consumers, restrict the ability to differentiate tobacco products, create a competitive advantage or disadvantage for certain tobacco companies, impose additional manufacturing, labeling or packing requirements, require the recall or removal of tobacco products from the marketplace (including without limitation as a result of product contamination), interrupt manufacturing or otherwise significantly increase the cost of doing business, or restrict or prevent the use of specified tobacco products in certain locations or the sale of tobacco products by certain retail establishments, may have a material adverse impact on the business, consolidated results of operations, cash flows or financial position of Altria Group, Inc. and its tobacco subsidiaries.

**Tobacco products are subject to substantial taxation, which could have an adverse impact on sales of the tobacco products of Altria Group, Inc.’s tobacco subsidiaries.**

Tobacco products are subject to substantial excise taxes, and significant increases in tobacco product-related taxes or fees have been proposed or enacted and are likely to continue to be proposed or enacted within the United States at the state, federal and local levels. Tax increases are expected to continue to have an adverse impact on sales of the tobacco products of our tobacco subsidiaries through lower consumption levels and the potential shift in adult consumer purchases from the premium to the non-premium or discount segments or to other low-priced or low-taxed tobacco products or to counterfeit and contraband products. Such shifts may have an adverse impact on the reported share performance of tobacco products of Altria Group, Inc.’s tobacco subsidiaries. For further discussion, see *Tobacco Space - Business Environment - Excise Taxes* above.

**Our tobacco businesses face significant competition and their failure to compete effectively could have an adverse effect on the business of Altria Group, Inc.’s tobacco subsidiaries.**

Each of Altria Group, Inc.’s tobacco subsidiaries operates in highly competitive tobacco categories. Settlements of certain tobacco litigation in the United States, among other factors, have resulted in substantial cigarette price increases. PM USA faces competition from lowest priced brands sold by certain United States and foreign manufacturers that have cost advantages because they are not parties to these settlements. These manufacturers may fail to comply with related state escrow legislation or may avoid escrow deposit obligations on the majority of their sales by concentrating on certain states where escrow deposits are not required or are required on fewer than all such manufacturers’ cigarettes sold in such states. Additional competition has resulted from diversion into the United States market of cigarettes intended for sale outside the United States, the sale of counterfeit cigarettes by third parties, the sale of cigarettes by third parties over the Internet and by other means designed to avoid collection of applicable taxes, and imports of foreign lowest priced brands. USSTC faces significant competition in the smokeless tobacco category and has experienced consumer down-trading to lower-priced brands. In the cigar category, additional competition has resulted from increased imports of machine-made large cigars manufactured offshore.

**Altria Group, Inc. and its subsidiaries may be unsuccessful in anticipating changes in adult consumer preferences, responding to changes in consumer purchase behavior or managing through difficult economic conditions.**

Each of our tobacco and wine subsidiaries is subject to intense competition and changes in adult consumer preferences. To be successful, they must continue to:

- promote brand equity successfully;
- anticipate and respond to new and evolving adult consumer preferences;
- develop, manufacture, market and distribute products that appeal to adult consumers (including, where appropriate, through arrangements with, or investments in, third parties);
- improve productivity; and
- protect or enhance margins through cost savings and price increases.

See *Tobacco Space - Business Environment - Summary* above for additional discussion concerning evolving adult tobacco consumer preferences, including increased consumer awareness of, and expenditures on, e-vapor products. Continued growth of this product category could further contribute to reductions in cigarette consumption levels and cigarette industry sales volume, and could adversely affect the growth rates of other tobacco products.

The willingness of adult consumers to purchase premium consumer product brands depends in part on economic conditions, which could have a material adverse effect on the business, consolidated results of operations, cash flows or financial position of Altria Group, Inc. and its subsidiaries. In periods of economic uncertainty, adult consumers may purchase more discount brands and/or, in the case of tobacco products, consider lower-priced tobacco products. Our tobacco and wine subsidiaries work to broaden their brand portfolios to compete effectively with lower-priced products.

Our financial services business (conducted through PMCC) holds investments in finance leases, principally in transportation (including aircraft), power generation and manufacturing equipment and facilities. Its lessees are also subject to intense competition and economic conditions. If parties to PMCC’s leases fail to manage through difficult economic and competitive conditions, PMCC may have to increase its allowance for losses, which would adversely affect our earnings.

**Altria Group, Inc.’s tobacco subsidiaries may be unsuccessful in developing and commercializing new product technologies that may reduce the health risks associated with current tobacco products and that appeal to adult tobacco consumers.**

Altria Group, Inc.’s tobacco subsidiaries continue to seek ways to develop and to commercialize new product technologies that may reduce the health risks associated with current tobacco products, while continuing to offer adult tobacco consumers (within and outside the United States) products that meet their taste expectations and evolving preferences. Potential solutions include tobacco-containing and nicotine-containing products that reduce or eliminate exposure to cigarette smoke and/or constituents identified by public health authorities as harmful. These efforts may include arrangements with, or investments in, third parties. Our subsidiaries may not succeed in their efforts. If they do not succeed, but one or more of their competitors does, our subsidiaries may be at a competitive disadvantage. Further, we cannot predict whether regulators, including the FDA, will permit the marketing or sale of such products with claims of reduced risk to consumers or whether consumers’ purchase decisions would be affected by such claims. Nor can we predict whether regulators will impose an unduly burdensome regulatory framework on such products. Any of these developments could adversely affect the commercial viability of any such new products.

**Altria Group, Inc. and its subsidiaries’ ability to grow new revenue streams may be limited if our operating companies are unable to move successfully into complementary products or processes.**

Altria Group, Inc. and its subsidiaries have adjacency growth strategies involving moves and potential moves into complementary products or processes. We cannot guarantee that these strategies, or any products introduced in connection with these strategies, will be successful. See the immediately preceding paragraph for a related discussion concerning new product technologies.

**Significant changes in tobacco leaf price, availability or quality could have an adverse effect on the profitability and business of Altria Group, Inc.’s tobacco subsidiaries.**

Any significant change in tobacco leaf prices, quality or availability could adversely affect our tobacco subsidiaries’ profitability and business. For a discussion of factors that influence leaf prices, availability and quality, see *Tobacco Space - Business Environment - Tobacco Price, Availability and Quality* above.

**Because Altria Group, Inc.’s tobacco subsidiaries rely on a few significant facilities and a small number of significant suppliers, an extended disruption at a facility or in service by a supplier could have a material adverse effect on the business, the consolidated results of operations, cash flows or financial position of Altria Group, Inc. and its tobacco subsidiaries.**

Altria Group, Inc.’s tobacco subsidiaries face risks inherent in reliance on a few significant facilities and a small number of significant suppliers. A natural or man-made disaster or other disruption that affects the manufacturing operations of any of Altria Group, Inc.’s tobacco subsidiaries or the operations of any significant suppliers of any of Altria Group, Inc.’s tobacco subsidiaries could adversely impact the operations of the affected subsidiaries. An extended disruption in operations experienced by one or more Altria Group, Inc. subsidiaries or significant suppliers could have a material adverse effect on the business, the consolidated results of operations, cash flows or financial position of Altria Group, Inc. and its tobacco subsidiaries.

**Altria Group, Inc. may be unable to attract and retain the best talent due to the impact of decreasing social acceptance of tobacco usage and tobacco control actions.**

Our ability to implement our strategy of attracting and retaining the best talent may be impaired by the impact of decreasing social acceptance of tobacco usage and tobacco regulation and control actions. The tobacco industry competes for talent with the consumer products industry and other companies that enjoy greater societal acceptance. As a result, we may be unable to attract and retain the best talent.

**Acquisitions or other events may adversely affect Altria Group, Inc.’s credit rating and Altria Group, Inc. may not achieve its anticipated strategic or financial objectives.**

Altria Group, Inc. from time to time considers acquisitions and may engage in confidential acquisition negotiations that are not publicly announced unless and until those negotiations result in a definitive agreement. Although we seek to maintain or improve our credit ratings over time, it is possible that completing a given acquisition or other event could impact our credit ratings or the outlook for those ratings. Furthermore, acquisition opportunities are limited, and acquisitions present risks of failing to achieve efficient and effective integration, strategic objectives and anticipated revenue improvements and cost savings. There can be no assurance that we will be able to acquire attractive businesses on favorable terms, that we will realize any of the anticipated benefits from an acquisition or that acquisitions will be quickly accretive to earnings.

**Disruption and uncertainty in the debt capital markets could adversely affect Altria Group, Inc.’s access to the debt capital markets, earnings and dividend rate.**

Access to the debt capital markets is important for us to satisfy our liquidity and financing needs. Disruption and uncertainty in the credit and debt capital markets and any resulting adverse impact on credit availability, pricing and/or credit terms may negatively affect the amount of credit available to us and may also increase our costs and adversely affect our earnings or our dividend rate.

**Altria Group, Inc.’s reported equity earnings in SABMiller may be adversely affected by unfavorable foreign currency exchange rates.**

For purposes of financial reporting, the earnings of SABMiller are translated into U.S. dollars from various local currencies based on average exchange rates prevailing during a reporting period. During times of a strengthening U.S. dollar against these currencies, our reported equity earnings in SABMiller will be reduced because the local currencies will translate into fewer U.S. dollars.

**Altria Group, Inc. may be required to write down intangible assets, including goodwill, due to impairment, which would reduce earnings.**

We periodically calculate the fair value of our goodwill and other intangible assets to test for impairment. This calculation may be affected by several factors, including general economic conditions, regulatory developments, changes in category growth rates as a result of changing adult consumer preferences, success of planned new product introductions, competitive activity and tobacco-related taxes. If an impairment is determined to exist, we will incur impairment losses, which will reduce our earnings.

**Competition, unfavorable changes in grape supply and new governmental regulations or revisions to existing governmental regulations could adversely affect Ste. Michelle’s wine business.**

Ste. Michelle’s business is subject to significant competition, including from many large, well-established domestic and international companies. The adequacy of Ste. Michelle’s grape supply is influenced by consumer demand for wine in relation to industry-wide production levels as well as by weather and crop conditions, particularly in eastern Washington. Supply shortages related to any one or more of these factors could increase production costs and wine prices, which ultimately may have a negative impact on Ste. Michelle’s sales. In addition, federal, state and local governmental agencies regulate the alcohol beverage industry through various means, including licensing requirements, pricing, labeling and advertising restrictions, and distribution and production policies. New regulations or revisions to existing regulations, resulting in further restrictions or taxes on the manufacture and sale of alcoholic beverages, may have an adverse effect on Ste. Michelle’s wine business. For further discussion, see *Wine Segment - Business Environment* above.

**The failure of Altria Group, Inc.’s information systems to function as intended, or the penetration by outside parties intent on disrupting business processes, could result in significant costs, loss of revenue, assets or personal or other sensitive data and reputational harm.**

Altria Group, Inc. and its subsidiaries use information systems to help manage business processes, collect and interpret business data and communicate internally and externally with employees, investors, suppliers, customers and others. Many of these information systems are managed by third-party service providers. We have backup systems and business continuity plans in place and we take care to protect our systems and data from unauthorized access. Nevertheless, failure of our systems to function as intended, or penetration of our systems by outside parties intent on extracting or corrupting information or otherwise disrupting business processes, could result in loss of revenue, assets or personal or other sensitive data, cause damage to the reputation of our companies and their brands and result in legal challenges and significant remediation and other costs to Altria Group, Inc. and its subsidiaries.

**Unfavorable outcomes of any governmental investigations could materially affect the businesses of Altria Group, Inc. and its subsidiaries.**

From time to time, Altria Group, Inc. and its subsidiaries are subject to governmental investigations on a range of matters. We cannot predict whether new investigations may be commenced or the outcome of such investigations, and it is possible that our business could be materially affected by an unfavorable outcome of future investigations.

**Expanding international business operations subjects Altria Group, Inc. and its subsidiaries to various United States and foreign laws and regulations, and violations of such laws or regulations could result in reputational harm, legal challenges and/or significant costs.**

While Altria Group, Inc. and its subsidiaries are primarily engaged in business activities in the United States, they do engage (directly or indirectly) in certain international business activities that are subject to various United States and foreign laws and regulations, such as the U.S. Foreign Corrupt Practices Act and other laws prohibiting bribery and corruption. Although we have a Code of Conduct and a compliance system designed to prevent and detect violations of applicable law, no system can provide assurance that it will always protect against improper actions by employees or third parties. Violations of these laws, or allegations of such violations, could result in reputational harm, legal challenges and/or significant costs.

## Controls and procedures

As filed, 866 characters.

Altria Group, Inc. carried out an evaluation, with the participation of Altria Group, Inc.’s management, including Altria Group, Inc.’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of Altria Group, Inc.’s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. Based upon that evaluation, Altria Group, Inc.’s Chief Executive Officer and Chief Financial Officer concluded that Altria Group, Inc.’s disclosure controls and procedures are effective.

There have been no changes in Altria Group, Inc.’s internal control over financial reporting during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, Altria Group, Inc.’s internal control over financial reporting.

## Risk factors

As filed, 504 characters.

Information regarding Risk Factors appears under *Cautionary Factors That May Affect Future Results* in Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations of this Form 10-Q and in Part I, Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2013 (“Form 10-K”). Other than as set forth in Part I, Item 2 of this Form 10-Q, there have been no material changes from the risk factors previously disclosed in our Form 10-K.

Filed Jul 22, 2014.
Source: SEC EDGAR, the filing index for accession 0000764180-14-000059. Last ingested by Listed: Oct 29, 2026, 12:29 ET. No prices; not investment advice.
